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Executive summary  
Diagnosis of Atrial Fibrillation (AF) after stroke is a national priority. AF-related strokes 
typically cost twice as much to manage as non-AF related strokes (Miller et al, 2005). If 
diagnosed with AF, further stroke can be reduced by 60% by taking medications such as 
anticoagulants. Because AF can be paroxysmal- that is the heart can go in and out of AF- it is 
not always detected during hospitalisation for stroke. If there is a reasonable suspicion that 
stroke may have resulted from undetected AF, guidelines recommend screening with a Holter 
monitor - an ambulatory electrocardiogram (ECG) applied in a hospital clinic for 72 hours. 
A ‘Test of Change’ within one local hospital in Scotland (NHS Lanarkshire) was conducted 
during 2019 where a new managed service involving devices (applied to n=64 patients) were 
considered for AF screening that would allow for up to 14 days of continuous monitoring in 
the home setting. This new technology enabled service also included reporting conducted by 
the company providing the service as a proposed alternative to clinicians inside the NHS doing 
all the report reading and analysis. Clinicians and other key implementers involved in the 
planning, set up, delivery, and evaluation of this service innovation were interviewed 
throughout the project to gather qualitative data on the potential barriers and facilitators to 
this type of service working longer term locally for them and or potentially scaling nationally. 
Patient experience was also captured through interviews with a sample of patients who 
received the new service (8/64; 12.5%) to capture acceptability of the new device and 
resulting service within this NHS setting. 
Findings revealed that patients found the new monitoring device acceptable. Stroke clinicians 
and nurses invested additional time in training (4 half days) to use the software, apply the 
devices and in home-visits to apply devices but also highly valued the availability of 14 days 
of continuous data. For further adoption of this type of service, it is critical to explore whether 
clinicians would adopt a system or service that produces the reports for them or whether they 
would prefer to have the reports generated by NHS staff (trust and control versus cost and 
capacity for reporting).  
It is anticipated that this report will benefit policy makers in government, operational 
managers, clinical leads, service managers and digital and IT managers and leads and many 
others by providing key barriers and facilitators and therefore a realistic checklist of what 
must be considered in planning for implementation of new technology enabled services to 
monitor for intermittent AF within a care pathway. 
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1 Aims and objectives 
 
The aim of this evaluation was to qualitatively explore the patient, clinical, and organisational 
experiences and acceptance of adopting and scaling a new technology enabled service for 14-
day continuous monitoring in the AF screening pathway in secondary care. 
The report will meet the following objectives in order to meet this aim: 
 
CHAPTER 2 Present the background, context and motivation for a new technology 
enabled pathway for AF screening after stroke. 
 
CHAPTER 3 Identify and evaluate currently available home-based AF continuous 
screening devices and the evidence that exists around their use and 
acceptance. 
 
CHAPTER 4 Describe the methods used to evaluate the patient, professional and 
implementation experience stories with this new AF care pathway. 
 
CHAPTER 5 Understand and map the existing AF pathway in one local context in 
NHS Lanarkshire. 
 
CHAPTER 6 Understand and map a real live ‘Test of Change’ new technology 
enabled care pathway for AF screening carried out in NHS Lanarkshire. 
 
CHAPTER 7 Report on the patient and professional acceptance and experiences of 
the new AF screening technology and service around it. 
 
CHAPTER 8 Report on the implementation experience (Process of clinical and 
service delivery) from the testing of the new AF screening pathway. 
 
CHAPTER 9 Present recommendations for future work implementing new 
technology enabled AF screening nationally.  
 
  
7 
 
2 Background and Context 
 
2.1 Atrial Fibrillation 
Atrial Fibrillation (AF) is a cardiac arrhythmia affecting the top sections of the heart (atria) and 
can lead to ischaemic stroke. As the heart is pumping irregularly, not all of the blood is being 
forced out of the heart and blood can collect in the atria allowing clots to form. Some factors 
are reported to increase the risk of clotting (e.g. older age and having a history of stroke). If 
any blood clots travel directly to the brain and restrict blood to the brain tissue this is known 
as an ischaemic stroke. AF is associated with a five-fold increase risk of stroke (The Framington 
Heart Study; Wolf et al, 1983). Although the severity of a stroke is dependent on the 
individual, AF related strokes are often more severe and may negatively impact the persons 
quality of life.  
Prevalence of AF in the UK is estimated at 1.2 million people and it is reported that 0.5 million 
individuals or more may be undiagnosed with AF (Stroke Association, 2017). In Scotland the 
current figures are just over 96,000 (BHF, 2018). people being diagnosed with AF with up to 
50,000 with AF but without a diagnosis (BHF, 2018). The cost of a single stroke is estimated 
to cost the NHS between £9,500 and £14,000. This is estimated to cost the NHS £2.8 billion 
per year (Spieler et al, 2002; Brüggenjürgen et al, 2007). Current healthcare provisions for 
stroke through the NHS, private healthcare or un-paid care are estimated to cost the UK £26 
billion per year (Stroke Association, 2018). As AF related strokes cost more than strokes from 
other causes, there is a significant financial impact of stroke on Scottish health and social care 
systems resources (BHF, 2018). 
Frequently AF is first detected during hospitalisation for stroke or transient ischaemic attack 
(Stroke Association, 2017). Almost 25% of all ischaemic strokes are thought to be related to 
AF (Yin et al, 2017). If diagnosed with AF, further stroke can be reduced by 60% by taking 
medications such as anticoagulants (Lip et al, 2007). AF can be asymptomatic, and frequently 
is first detected at time of admission for an acute stroke. However, AF can also be paroxysmal, 
meaning that the heart can change between a regular normal rhythm and AF. If there is a 
reasonable suspicion based on the presentation of stroke and clinical signs, but the patient is 
in a normal heart rhythm at the time of stroke, then international guidelines recommend 
monitoring the patient for 72 hours to determine if paroxysmal AF is present and therefore 
treatment of AF with an oral anticoagulant drug is recommended.  
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2.2 Current AF screening technology 
In the first instance, a 12-lead ECG is recorded in hospital. This 12 lead ECG captures a 30 
second snapshot of the electrical rhythm of the heart from different viewpoints. Patients may 
be monitored via telemetry during their hospital stay but because AF can be paroxysmal, it 
might not be present during hospitalisation. If there is a reasonable suspicion that AF is the 
cause of stroke, then a Holter monitor, which is an ambulatory ECG may be applied for up to 
72 hours (ESC, 2016). While debate remains about the precise amount of AF that leads to 
stroke, it is clear that the longer patients are monitored for, the more likely it is that AF will 
be detected. It has been proposed therefore that longer term monitoring via newer 
technologies should be considered to capture potential asymptomatic AF in this population 
(Verma et al, 2014; January et al, 2014; Kirchhoff et al, 2016).  
A cross-party inquiry examining the management of Atrial Fibrillation (AF) specifically within 
Scotland recently recommended investments in the use of new technologies to improve the 
rates of earlier AF screening (BHF, 2018). Although a wide range of AF screening devices to 
allow longer monitoring periods are becoming more readily available (such as handheld 
devices, single lead monitors and adhesive devices), some may not be appropriate to use 
(either for some patient populations or for some clinical contexts). It is important therefore 
to explore which of these might be acceptable by both patients and clinician’s and also 
evaluate if and how these can be incorporated into the current AF screening pathways to 
improve AF screening, diagnosis and resulting treatment.  
A scoping review of current evidence for AF screening technology is provided in Chapter 3.  
A situational market review of AF technologies conducted by the DHI prior to this project 
(during 2018-2019) can be found in Appendix 1. 
 
2.3 Improving AF screening with new Technology Enabled Care Pathways 
New technologies have shown great potential at improving the quality of health and care 
from the perspective of the patient, workforce and healthcare system (Health Education 
England, 2018). Implementation of technology within health and care has also been accepted 
by patients and has been reported to empower patients, improve independence and allow 
further care in the community. This has also allowed the provision of new roles associated 
with technology and reduced the cost of long-term health care (Castle-Clarke, 2018). 
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Technology implementation projects have often been completed poorly in large scale projects 
and often result from trials that are very specific to the population and/or context they are 
trialled in (Greenhalgh et al, 2017; Castle-Clarke, 2018). Researchers have frequently 
highlighted that the process of implementing technology within the NHS should be better 
reported, providing further details regarding the benefits and challenges of the 
implementation process (Castle-Clarke, 2018). As technology advances at pace it is crucial 
that we examine how these newly emerging devices and care delivery pathways are accepted 
(or not) by patients and also how they can be adopted and integrated into existing or even 
new clinical pathways to improve or disrupt the current status quo in order to reach better 
targets for screening and ultimately deliver the appropriate care in a timelier way. This will 
include looking at innovative managed service models and how these can be implemented 
and scaled up across the national health system more widely. 
 
2.3.1 The Digital Health and Care Institute 
The Digital Health & Care Institute (DHI) is part of the Scottish Funding Council’s Innovation 
Centre Programme, which is designed to support user and patient centred innovation in the 
digital health and care sector. They do this in part by fostering collaboration between 
universities, businesses, third sector and civic partners to adopt new innovative care 
pathways. By working collaboratively with a variety of experts including, academics, industry 
and service providers and service recipients (patients, service users and citizens) they also 
examine the whole process of implementation (which includes designing, developing, 
evaluating, and implementing) of new devices, managed services, and care pathways within 
the current healthcare system. They also aim to drive forward commercial and economic 
growth in the sector by understanding best practices and new ways of working between 
innovative technology companies and healthcare providers (DHI Scotland, 2018). 
One of the DHIs supported national challenges focuses on examining the implementation of 
new Atrial Fibrillation (AF) screening service in the care of individuals who have had a stroke. 
DHI have previously undertaken work in partnership with Scottish Government in the 
screening of AF in primary care (BHF, 2015). This project builds on this work by examining the 
role of new AF screening technologies and pathways in secondary care. 
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2.3.2 The Context: NHS Lanarkshire 
To provide a basis for national rollout of the use of new digital services to monitor AF, this 
study will use one implementation site as a case study. This site was NHS Lanarkshire in 
Scotland UK (see Figure 2.1). NHS Lanarkshire are an innovation ready service within Scotland 
and they currently provide stroke services for around 10% of the Scottish population (574,637 
out of 5,295,403) (National Records of Scotland, 2011). It contains a representative mix of 
rural and urban populations. The population is served by three distinct district general 
hospitals, each with cardiac physiology departments that work in different ways.  
 
 
Figure 2.1. Diagram of NHS Lanarkshire sites. Used with permission, Michael Brady, 
Medical Illustration, NHS Lanarkshire, 07.02.2020. UHH is University Hospital Hairmyres, 
UHM is University Hospital Monklands and UHW is University Hospital Wishaw 
 
 
  
11 
 
In NHS Lanarkshire they aim to conduct prolonged ECG monitoring to detect paroxysmal AF 
in stroke patients with (i) no known history of AF and no contraindication or definite indication 
for lifelong oral anticoagulation, with any of the following: 
i. History of frequent palpitation 
ii. Syncope or pre-syncope 
iii. Recent myocardial infarction 
iv. Recent cardiac surgery 
v. Cardiac failure 
vi. Ischaemic stroke/TIA affecting more than one vascular territory 
vii. A cortical ischaemic stroke/TIA with no other explanation 
In NHS Lanarkshire, 72 hour tapes can be applied on all appropriate patients, however, these 
cannot be reported within the desired time frame. NHS Lanarkshire are ready as an 
organisation to innovate and saw an opportunity to improve this service with support from 
DHI. 
 
2.3.3 The role of University of Strathclyde 
The University of Strathclyde were commissioned to conduct a qualitative process evaluation 
of this live implementation or ‘Test of Change’ in order to capture how the device and service 
around this were chosen, used, and accepted by both the patients receiving the device and 
the clinicians and health professionals involved in applying the device, reading the reports, 
and diagnosing AF cases (the full service pathway). Edinburgh Napier University collaborated 
with the University of Strathclyde to provide academic and clinical advice on screening of AF. 
This type of pragmatic real time evaluation is crucial in order to understand if and how this 
new pathway would work in practice in the longer term for NHS Lanarkshire but to also 
identify what the key barriers and facilitators are for the wider adoption and scaling of similar 
solutions nationally across other health boards in Scotland and beyond.   
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3 Scoping Review 
What does the existing literature say about available AF screening technology? 
 
This scoping review aimed to identify existing AF screening technology which would be 
suitable for individuals who have had a stroke and review what evidence exists (and what 
gaps there might be) for the use of these devices in practice. We identify devices which are 
currently used for short periods but can be used for longer periods of time (more than 72 
hours) to achieve to the recommended screening time in this population (Kirchhoff, 2016; ISD 
Scotland; 2017).  
This scoping review therefore aimed to identify technology which:  
• Can continuously monitor cardiac rhythms for more than 72 hours (essential) 
• Has been used for screening for AF individuals who have had a stroke (essential) 
• Has evidence of patient involvement/feedback (desired) 
 
Note: This review excluded implantable devices due to high cost and invasive nature of 
procedure. 
3.1 Search Method 
 
The database PubMed was searched on 4th Sept 2019 by one researcher SH. The full search 
criteria can be found in Appendix 2. Literature was restricted to English, full text and being 
published in the last 10 years. The resulting papers were reviewed to identify AF screening 
technology used in individuals who have had a stroke and to evaluate the reported usability 
of the technology found in the existing literature.  
3.2 Findings 
 
Thirty-two pieces of literature met the outlined criteria above. An overview of the available 
technology that was reviewed is presented in Table 3.1. The full set of findings for this review 
have been presented in Table 1 in Appendix 3.  
An initial market review of devices was also conducted by DHI earlier in the project (before 
devices were selected and implemented in NHS Lanarkshire) and for reference this can be 
found in Appendix 1. 
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Technology  Device Category  Device subcategory reported Summary of type of device Device examples in general literature No. different devices 
identified in the 
literature review.   
Technology to 
assess heart rate.  
Non-ECG 
monitoring  
Pulse palpation Assessment of heart rhythm by radial pulse. NA. Fitzmaurice et al, 2014. N=1  
BP machine  Device measures the last 10 pulse intervals during cuff 
deflation and calculates the mean and SD of the time 
intervals.  
WatchBP Home 
Kearley et al, 2014 
N=2  
Technology to 
assess heart 
rhythms.  
Handheld 
technology 
Photoplethysmography (PPG)device Device uses light passing through skin to detect blood 
volume changes in the microvascular bed of tissue.  
Cardiio Rhythm smartphone application  
Tang et al. 2017. 
N=0 
Smart phone + case electrode Phone case assesses rhythm providing a single lead rhythm 
strip. 
AliveCor Kardia  
Galloway et al, 2013. 
N=2. 
Electrode stick Device assesses rhythm providing a single lead rhythm 
strip. 
MyDiagnostick  
Tieleman et al, 2014 
N= 0 
Single lead monitoring device.  Device assesses rhythm providing a single lead rhythm 
strip. 
Zenicor-ECG  
Poulsen et al, 2017 
N= 1. 
ECG screening 
(single lead) 
Monitoring patch.  Patch includes electrode to assess rhythm providing a single 
lead rhythm strip. 
Zio patch  
Tung et al. 2015. 
N=2 
Wrist/watch recorder Device assesses rhythm providing a single lead rhythm 
strip. 
AliveCor Kardia Band 
Bumgarner et al. 2018. 
N=0.  
 
ECG screening 
(multi lead) 
Wearable device Available devices include products with straps or devices in 
clothes. 
Worn like necklace.  
Textile Wearable 
Holter (vest device)  
Pagola et al. 2018. 
N= 1.  
Holter monitor Currently used with NHS. Sposato et al,.2012.  N= 26.  
ECG Gold standard in screening Lazzaro et al, 2012.  N= 13.  
Continuous ECG  Gold standard in screening, required in hospital stay.  Scheitz et al,. 2015.  N= 4. 
Table 3.1. Table summarising different devices available in the general literature and devices identified in this literature review which provide 
continuous monitoring in the stroke population identified in this literature review.  
Please note, due to the focus of the review, studies or devices that were identified in the general literature but were not identified as providing continuous 
monitoring were listed as n=0.  
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This scoping review was intended to provide the reader context in relation to some of the 
other currently available devices for measuring heart rhythm and to review what potential 
evidence is available and acceptable for use in individuals who have had a stroke. The scoping 
review found that in general the available AF screening technology either used an ECG, 
photoplethysmography, or ossilometric assessment of regularity of heart rhythm. Studies 
which do not use ECG technology are not the primary focus of this scoping review, as they 
require further follow up if an irregular rhythm is identified. Similarly, the review of single-
time point monitoring provided here is not exhaustive, as the primary focus of this work is 
longer term monitoring to detect paroxysmal AF. 
 
Single time point monitoring studies 
One recent systematic review examined twenty four studies which identified AF using a single 
time point device (Lowres et al, 2019). The devices identified in the single time point 
systematic review included: 12 lead ECG (n=5) (one of these studies used an ECG to confirm 
AF identified by pulse palpation); single lead (Omron HCG-801) (n=1); single lead ECG 
(AliveCor) n=6; single lead ECG (MyDiagnostick) (n=1); single lead ECG (HeartCheck, 
CardioComm ) (n=2); Pulse palpation n=3; modified blood pressure machine (Microlife 
WatchBP Home A ) (n=2); single lead ECG (lead II during cardiac CT scan) (n=1) (Lowres et al, 
2019). Nineteen of these twenty four studies agreed to collaborate and share the patient level 
data. From this collective data, it was noted that n=141,220 participants were screened across 
the studies, and AF was identified in n=1,539 cases.  
 
Using handheld technology to assess heart rhythm 
Four studies were noted to use handheld technology which assessed heart rhythm to identify 
AF, specifically Zenicor Medical handheld products (Levin et al, 2014; Engdahl et al, 2013; 
Poulsen et al, 2017; Doliwa Sobocinski et al, 2012). All four of these studies used a 
combination of intermittent and continuous monitoring (using Holter monitors) for varying 
time periods (24 hours – 30 days). One of these studies also additionally used ECG technology 
to aid diagnosis of AF (Engdahl et al, 2013). Doliwa Sobocinski et al, 2012 and Levin et al, 2015 
reported diagnosing AF in 17 individuals (out of 249) over a period of 30 days using an 
intermittent screening using a handheld device in addition to a Holter monitor. Levin et al, 
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2015 also provides a cost effectiveness analysis which reported the continuous monitor as 
being less cost effective than intermittent screening because it was more costly and had less 
sensitivity.  
Poulsen et al, 2017 noted that 20 individuals had AF diagnosed but only ten individuals (37%) 
had AF recorded on both the Holter monitor and handheld ECG device. A Holter monitor can 
provide a continuous ECG reading, a handheld device can provide intermittent ECG readings.  
Engdahl et al (2013) reported that 40 (out of 848) individuals were diagnosed with AF, 10 of 
these diagnosed by an ECG and 30 of these by using the handheld device. Poulsen et al. 2017 
reported that 22% of patients were excluded from their study due to physical or cognitive 
impairments which limited their ability to hold the device, and this is noted as an important 
consideration in individuals who have had a stroke. Poulsen et al (2017) report that when 
compared to the Holter monitor, the sensitivity of the thumb ECG was 59% and the specificity 
was 87%. Although limited information is provided about the quality of the reports, Poulsen 
et al (2017) noted that 13% of handheld ECGs were of poor quality and not useable, noting 
that this was due to the age of participants and ability to hold the device. Poulsen et al (2017) 
also noted that patients appeared more bothered wearing the Holter monitor compared to 
the intermittent screening handheld device. Engdahl et al (2013) reported that the ability to 
hold the device was assessed by the nurse in their study but the findings of this are not 
reported. As this was assessed, it could be argued that this further supports the importance 
of the potential limitations in individuals who have had a stroke and may have difficulty 
holding devices. In summary, none of the handheld devices from these studies were solely 
able to provide continuous monitoring, meaning that participants were required to wear 
more than one device. Furthermore, the suitability of handheld devices may be limited to 
individuals who have the cognitive and physical ability and strength to hold the device for the 
required length of time.  
Single Lead Continuous Monitoring Devices 
Two studies reported the use of single lead monitoring devices (Lumikari et al. 2019; Akiyama 
et al, 2017). The first study, a clinical trial by Lumikari et al (2019) used a single lead device 
for up to four weeks and a 12 lead ECG, identifying AF in seven individuals (out of 75). Four of 
the seven cases identified were asymptomatic of AF. This clinical trial was the longest 
continuous screening period noted in this review. This study reported 18 patients had 80% of 
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ECG monitoring which was considered good quality. The next study considered (Akiyama et 
al, 2017) was a case study which used a single lead monitoring device to screen for AF for a 
period of 11 days. AF was noted on two separate occasions on day 5 and day 9 in this 
individual. The small size of the device, its application on the centre of the chest and being 
wireless were noted as factors which led to clearer ECG readings.  
Researchers reported some poorer quality ECG. This may be due to the adhesive patch drying 
out as participants either did not change the patch regularly or when replacing the skin patch, 
the position was poor. Ability to continuously record heart rhythm, compact size and ease of 
the device for the patient were factors which influenced the choice of this device. However, 
skin irritation was reported in two individuals. Skin integrity and application of devices may 
therefore also be an important aspect of consideration especially in the population 
considered for this study. It is also important to note that two devices were reported as being 
damaged due to showering, so this may mean that activities of daily life may be impacted by 
current screening technologies. 
Multi-Lead Monitoring Devices 
Yayehd et al, 2015 evaluated the use of a wearable three lead device, worn by patients for 21 
days, identifying 2 individuals with AF out of 56. Researchers in this study note a potential 
limitation is the small sample size within this research study. A major benefit of this research 
study is the length of time the device was worn for an extended period of time (21 days).  
Throughout this scoping review, a high prevalence of research studies (n=26) reported the 
use of multi lead devices referred to as Holter monitors. The majority of studies reported use 
of a Holter monitor in addition to other devices such as 12-lead ECG devices (n=8) (Arevalo-
Manso et al, 2016; Thakkar and Bagarhatta, 2014; Suissa et al, 2014; Higgins et al, 2013; 
Yodogawa et al, 2013; Suissa et al, 2013; Lazzaro et al, 2012; Gumbinger et al, 2012) and 12-
lead continuous beside monitor (n=2) (Lazzaro et al, 2012; Sposato et al, 2012). Variability of 
the types of Holter monitors was noted in a review completed by the Digital Health and Care 
Institute (2018) and this has been included with permission in Appendix 1 for reference.  
In addition to a Holter monitor (six leads), one study used mobile data transmission 
(Policardiógrafo IP) (PoIP) software to transmit the recordings in real time to allow analysis 
(Sampaio et al, 2018). Researchers acknowledge the small sample size (n=52). Researchers 
also noted issues related to low signal strength related to 2G and 3G transmission issues 
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(6.8%), issues which can be expected to be reduced when using 4G technology. Patients in 
the control group were noted to have greater data loss, but researchers note this is due to 
the increased amount of freedom this group were given to move and poor reception may 
have impacted this.  
Many of these studies did not appear to consider important factors such as patient comfort 
or acceptability, both of which are key components that could facilitate wider scale adoption 
of these technologies in larger scale screening programmes moving forward. 
3.3 Discussion 
 
Paroxysmal AF can be harder to identify due to its intermittent occurrence. Hariri et al (2016) 
suggest that devices with continuous monitoring may increase the likelihood of capturing an 
episode of intermittent AF. Limitations relating to patient inconvenience and compliance are 
also reported with existing technology (Poulsen et al, 2017). However, a recent literature 
review and meta-analysis suggests newer portable devices may provide an alternative option 
for continuous screening for AF compared to the current use of Holter monitors (Ramkumar 
et al, 2018). The review by Ramkumar et al (2018) suggested that intermittent screening (of 
less than 20 minutes over a period of time) may provide a screening rate similar to the results 
of a continuous Holter monitor worn over 24 hours but highlight that due to differences in 
reporting between studies, the regularity at which intermittent screening occurred could not 
be distinguished. Furthermore, the authors acknowledged the use of such a device is best 
placed in those who have symptomatic AF and are compliant with using the device regularly 
(Ramkumar et al, 2018).  
Although advancing technology provides great potential for the use of single time point 
devices for the general population, this may be limited in those who have reduced 
independence and reduced mobility or whose ability to wear or hold devices may be difficult. 
This difficulty does not reduce the importance of continuous monitoring in patients who have 
had a stroke and have a higher risk of further stroke. Therefore, identifying suitable devices 
which are easily applied, wearable, and have higher user acceptability may increase 
compliance of wearing the device and potentially the quality of the data received from the 
device. Most focus on suitability or usability has been placed on the quantitative assessment 
of the device, however a small number of studies have included the qualitative assessment 
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of the device. One pilot study conducted by Arevalo-Manso et al (2016) in Spain investigated 
the suitability of a wearable vest (textile wearable Holter) in individuals who have had a stroke 
(n=162). Although a small number of participants did not complete the monitoring period due 
to technical issues (n=8), non-compliance due to discomfort (n=8) the overall findings suggest 
that such a device is feasible in this population due to the user comfort (Pagola et,. al 2018). 
Although a wide range of AF screening devices to allow longer monitoring periods are 
available (such as handheld devices, single lead monitors and adhesive devices), some may 
not be appropriate to use in some individuals. Loss of ability, loss of independence and the 
reliance on others for lifelong care caused by stroke may mean using some AF screening 
devices will be more difficult to use. For example, a hand-held device (requiring both hands 
to use) may not be the most suitable technology to screen for AF in a person with limb 
weakness as some devices require good skin contact.  
Challenges associated with the use of new AF screening technology is documented 
throughout literature. Issues with poorly tested automatic algorithms may lead to over 
diagnosis and false positives, especially with other arrhythmias such as atrial tachycardia (AT) 
(Ramkumar et al, 2018). False positive rates may also be impacted by the large number of 
younger populations who are more likely to use technology devices independently and who 
are less likely to have AF when compared to an older generation (Singh et al, 2018; Ramkumar 
et al, 2018). Inconsistency between recommendations of the length of periods of AF which 
leads to a diagnosis may also lead to challenges for healthcare providers (Singh et al, 2018). 
Due to such challenges, some researchers are calling for further investigation for 
recommendations for the use of new AF screening technology within healthcare as availably 
published recommendations are quickly becoming outdated as devices and monitoring 
advances (Singh et al, 2018; Milani and Franklin, 2017; Hivert et al., 2017).  
One randomised control trial (Steinhubl et al., 2018) used a patch single lead monitor 
(iRhythm ZioXT) worn for up to four weeks to assess opportunistic screening implications on 
patient care. The findings of this RCT reported those who are at high risk of AF (such as 
those who have had a previous stroke/TIA) who had immediate and continuous monitoring 
had a higher diagnosis rate compared to those who had delayed monitoring which started 
four months after enrolment (Steinhubl et al., 2018). Another result of this RCT was the 
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increased utilisation of healthcare resources (Steinhubl et al., 2018). One potential 
limitation in this RCT was that it did not report the implications from the patient perspective 
such as technology acceptance, feasibility and device utility but rather it presented 
medically focused outcomes such as diagnosis rates (Steinhubl et al., 2018). Although this 
may not have been the main focus of this paper, other researchers have reported the Zio 
Patch validation or usability. For example, Rosenberg et al. (2013) reported no significant 
difference between the amount of AF measured when comparing the Zio patch and the 24 
hour Holter monitor. They also noted that it was well tolerated by participants, this was 
indicated by the mean length of time worn (10.8 ± 2.8 days).  
The identification of available single time point AF screening devices has been examined 
(Health Innovation Network South London. 2017). One report identified several single time 
point screening devices however, continuous monitoring was outside the scope of that 
review. This review identified two pilot studies completed in Australia, which evaluated used 
a single time point device in the general population (Lowres et al. 2014; Orchard et al, 2014). 
Eleven points have been identified for consideration when purchasing an AF single time point 
ECG screening device which can be applied to continuous monitoring devices.  
1. Setting of the device use; 
2. Staff involved;  
3. Device health, environmental and safety requirements;  
4. Device Accuracy;  
5. Data security and transmission;  
6. Device Memory;  
7. Consumables;  
8. Cost;  
9. MHRA guidance;  
10. ECG leads;  
11. Hardware. (Health Innovation Network South London. 2017).  
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AF is more likely to be asymptomatic and paroxysmal in patients who have had a stroke 
(Sanna et al, 2014; Kirchhof et al, 2016), this highlights the importance of continuous and 
immediate or early screening following a stroke outlined by recent guidelines (Kirchhof et al, 
2016). As already presented in Chapter 2, although AF screening in individuals who have had 
a stroke is reported as essential, due to limited funding and a reduction in devices (Tulloch, 
2018) the application of devices is often delayed. This highlights the importance of capturing 
the current care pathway early within the NHS. This step is also highlighted as an initial way 
to implement sustainable innovation (NHS Innovation, 2018). Despite this very few studies 
have considered the impact of the implementation of new continuous monitoring technology 
within the clinical care pathway. No study to date has reviewed the full implementation 
process of new AF continuous screening monitoring in individuals who have had a stroke.  
NHS Innovation (2018) has reported several case studies implementing technology within the 
current NHS care system. One case study reported the process of implementing the AliveCor 
Kardia device. The involvement of various healthcare professionals led to opportunistic 
screening in GP practices and in community pharmacies. Identified difficulties associated with 
using the device (such as poor readings in noisy environments) led to adapted training 
techniques. Furthermore, feedback from GP staff who identified additional and unnecessary 
workload occurred as a result led to a new care pathway for the patient being formed, 
reducing the time to access treatment from 12 weeks to 2 weeks. However, this study did not 
include patient experiences.  
Technology advances in this area are also likely to continue. For example, one recent study 
has highlighted the potential of and recent development of a phone application (Cardiio 
Rhythm) which has been shown to be 95% effective in identifying an irregular rhythm by 
measuring variations in the colour of the persons face. This removed the need of application 
to the skin, removing infection control concerns which may occur when using a multi-use 
device. The use of such a device, has the potential of allowing the identification of AF in a 
large group of people at one time (Freedman, 2016). Singh et al,. (2018) suggest that software 
adaptations may allow three-dimensional ECGs allowing more sensitive screening for other 
cardiac problems such as ST elevation (this is where the ST segment of an ECG is abnormally 
high) which indicates cardiac death (ischaemia) or QT changes. Issues relating to the 
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compatibility of new AF screening devices to current healthcare ICT systems may require 
adaption. For example, some AF screening devices produce a report in PDF format which may 
not be able to be added to patient clinical notes or require manual review or entry to ensure 
adequate documentation.  
3.4 Conclusions 
 
Further work is necessary to improve regulations and the quality of available devices suitable 
for screening in this population, improving the sensitivity, increasing patient comfort, 
reducing device size, improving user acceptability, whilst making costs acceptable (Murray 
and Krishnan, 2018). 
This scoping review focused on identifying suitable continuous AF screening device(s) (>72 
hours) for individuals who have had a stroke. The review highlights the need for the following: 
• The use of devices which have patient involvement in development, to ensure its 
suitability for use in the population (e.g. the hand-held device was not suitable for all 
participants who had a previous stroke, due to limited physical strength or ability). 
• The development of devices which have high sensitivity (to ensure accurate 
diagnosis). 
• The need for a study which describes the implementation process of short term 
continuous cardiac monitoring. 
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4 Process Evaluation: Methods 
This evaluation was led by University of Strathclyde and collaboratively developed by the 
University of Strathclyde (UoS), NHS Lanarkshire, Edinburgh Napier University (Prof Lis 
Neubeck), and the DHI design team (Angela Bruce).  
4.1 Purpose and Aim 
The aims of this evaluation were to:  
1. Map and understand both the current and future AF screening care pathways in 
NHS Lanarkshire Scotland (See Chapters 5 and 6) 
 
2. Capture Acceptance and User Experiences (UX) from (see Chapter 7) 
▪ (A) citizens/patients 
▪ (B) healthcare professionals and  
▪ (C) other people involved in implementation and adoption such as 
friends/family/carers, technology providers, commissioners  
 
3. Identify Barriers and Facilitators for wider implementation and adoption (see 
Chapter 8) 
 
Note: While the criteria of the device(s) selected was considered throughout the process of 
the project (outlined in Table 6.1), the purpose of this project was not to evaluate the device 
itself or its ability to monitor intermittent AF and diagnose it, but rather the process of 
implementation of innovative AF technology enabled services within NHS Lanarkshire and 
beyond.  
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4.2 Data Collection  
The evaluation used qualitative methods (interviews) with patients, clinicians, and other key 
implementers across the lifetime of the project to explore each of the stages of 
implementation (see Figure 4.1).  Patient Interviews were conducted by telephone and all 
other interviews were completed either face to face or by telephone. Some of the health care 
professional (HCP) and implementer sessions were done as round table discussions but were 
also semi-structured in nature and transcribed and analysed in the same way as the 
interviews. The semi structured interview schedules were developed by researchers at UoS 
and drew upon key components of the NASSS framework (see Appendix 10). 
All interviews were digitally audio-recorded. The audio recordings were transcribed by a third 
party (a data processing agreement was put in place for this process). The use of the 
professional transcriber improved the reliability of the data transcribed. Upon completion of 
the transcriptions, the identifiable audio files were deleted from the recording device. All 
focus group/interview transcripts were anonymised using un-identifiable pseudonyms. The 
audio-files stored on the researchers’ password protected computers on secure network 
drives (‘Strathcloud’) at the UoS were deleted at the end of the research project and once all 
reporting to funders was concluded in 2020.  
Although not the main focus, this project also captured some quantitative data for descriptive 
purposes (e.g. number of AF cases, devices returned, cost of reports, time to generate reports). 
Clinicians and or clinical researchers were asked to complete a CNR (case notes record) 
extraction data form developed for this project to collate the quantitative data for each 
individual patient. This task involved reviewing medical notes and reviewing the device report 
following analysis.  
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4.3 Participants 
NHS Lanarkshire recruited a total of 64 patients to experience the new service for AF 
screening from 1st July 2019-1st October 2019. Clinical leads and AF experts (key contributors) 
considered that a sample size of 60 participants was appropriate and achievable within this 
time frame and to capture a wide range of patient experiences.  
Given the findings from the scoping review presented in Chapter 3, the experience of patients 
was placed at high value, however, the view of health care professionals and other 
stakeholders involved in the pathways were of equal importance in order to better 
understand the perceived costs and benefits to patients, clinicians, service delivery and 
implementation and to identify the barriers and facilitators of new technology enabled AF 
services more widely. These were identified as gaps in the existing literature as outlined in 
Chapter 3. Table 4.1 provides an overview of the number of interview participants.  
 
Group Target Actual Number 
Patients & 
Relatives 
Traditional Pathway: 10  
New Pathway: 10 
NA (zero due to 
delayed start) 
N=8+1 
HCPs N= 10-20 over duration of project N= 12 
Other N= 8-10 over duration of project N=6 
Table 4.1 Overview of numbers of Interviews 
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Figure 4.1. Overview of methods across stakeholders and across timeline of 
implementation 
 
 
 
Methods: Data Collection
u Interviews
u Focus Groups
Patients and Relatives HCPs Implementers
Across Implementation Timeline
Across Stakeholder Groups
Initiation/
Set Up
Phase 1: 
Before 
Go Live
Phase 2:
During 
Go Live
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Patient Inclusion Criteria:  
• Adults aged 18 and over;  
• Able to provide informed consent;  
• Receiving/received services (including anticoagulant medication) by NHS Lanarkshire;  
• Are sufficiently proficient in English to be able to participate in data collection 
activities;  
• Are able to participate in sustained conversation with research team and/or are not 
considered cognitively impaired;  
• Have experienced Atrial Fibrillation screening services in NHS Lanarkshire i.e. they 
have had investigations to screen for cardiac arrhythmias such as Atrial Fibrillation 
(which may include wearing a portable ECG monitor).  
Patients did not require a diagnosis of AF to have had experience of these services. 
Health Care Professional Inclusion Criteria: 
Given the multidisciplinary nature of stroke care, it was important to engage with a range of 
HCPs from NHS Lanarkshire throughout this evaluation. The following inclusion and exclusion 
criteria were used to screen the suitability of health care professionals for their suitability. 
• Members of the stroke care team in secondary care involved in the screening of AF 
following a stroke and/or have experience working with those who have been 
diagnosed with AF following a stroke.  
• Able to provide informed consent.  
• Able to communicate sufficiently well in English.  
• Knows of, or has experience of, the AF services whether that be a technological, 
personal, family, stakeholder or procurement experience of the services. 
Other  
• Knows of, or has experience of, the implementation process of the AF services 
whether that be a technological, stakeholder or funder experience of the 
implementation process. 
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4.4 Recruitment 
Convenience methods were used to recruit patients. HCPs acted as gatekeepers for all patient 
participants. The clinical team covers three hospital sites: University Hospital Hairmyres, 
University Hospital Monklands, and University Hospital Wishaw. HCPs received participant 
information leaflets from UoS either via post via clinical services and/or in person. Clinicians 
initially screened the patients’ suitability for this project in accordance to the criteria outlined 
above. Clinicians approached the patients and provided them with the participant 
information leaflet. It was made clear that not participating would not affect their standard 
of care. Patients still received the device (as part of their routine care) even if they chose to 
not take part in this evaluation.  
The Stroke Managed Clinical Network (MCN) team (which includes stroke specialist nurses) 
identified recent patients who met the inclusion criteria (n=67). For the new pathway 
evaluation, the Stroke MCN team identified and approached patients within the three stroke 
units involved. HCPs provided an overview of the project and an information leaflet. Sixty-
four individuals consented to wearing the device. Two individuals refused to participate, and 
clinicians felt that participation would not be appropriate for one patient. The information 
leaflet given included UoS research teams contact details. All patients were able to contact 
the UoS team directly for further details of the project. If the patient preferred to be 
contacted by the UoS team, clinicians were required to take preliminary consent to allow 
initial contact from the evaluation team at UoS. This preliminary consent was to allow the 
patients contact details to be sent to the UoS and was not considered as participation in the 
first instance. Contact details were sent from the clinician to UoS research staff from an 
nhs.net email address to an nhs.net email address in keeping with information governance 
guidelines. Informed consent was obtained at the beginning of evaluation sessions by the 
research team (UoS/GSA) before any evaluation activities or data collection in accordance 
with GCP guidelines. The UoS team either discussed the project in further detail to the 
potential participant over the phone or in person on the hospital site. Consent to participate 
was either taken over the phone or in person, however consent was always obtained by the 
UoS team prior to participation in the evaluation interviews. Consent for telephone interviews 
was also taken over the phone prior to the interview, this conversation was audio recorded 
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and transcribed by researchers at UoS. Of those who contacted UoS, only two patients 
refused to participate, a total of eight patients and one relative participated in the interviews 
(see Appendix 6).  
HCPs and other key stakeholders that were not patients were identified and approached 
through stakeholders and the Stroke MCN team for input throughout the evaluation. This also 
involved Strathclyde approaching external groups such as procurement teams, the device 
manufacturers, the service providers, and those involved nationally in decision making 
around AF services more widely.  
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Figure 4.2 Overview of Interviews. Note: Individual figures indicate the number of participants in each interview or group interview.
30 
 
 
4.5 Analysis and underlying theoretical frameworks 
Thematic analysis methods were used to analyse all of the data collected. This involves 
reading and becoming familiar with the data; creating a coding framework (set of codes) that 
describe the data (tagging quotes with these themes) and mapping and organising these into 
themes which are higher level labels to explain the concepts described by the coded data. 
This initial process was completed by one researcher who reviewed the qualitative data and 
noted main themes. Several transcripts were also coded by a second researcher, following 
this, initial main themes identified by the two researchers were then compared. In addition 
to traditional and well established physical post-it-note mapping and charting methods we 
also used NVivo version 12 to organise and manage our transcripts and conduct the coding. 
This software allowed the main themes to be supported with direct written quotations from 
the original data, ensuring clarity throughout the analysis process with the added benefit of 
allowing the participants words to be presented in the final report. The evaluation drew 
primarily upon the Non-adoption, Abandonment, Scale-up, Spread, and Sustainability 
(NASSS) framework (used in Greenhalgh et al, 2017) which looks more widely at complexity 
and context (see Figure 4.2). This considers:  
• the nature and factors of the condition 
• the technology (in this project the device) 
• the perceived value of the device for both the user and supplier 
• those involved in adopting and using the device 
• the capacity of the organisation for change and changes needed to make the 
intervention work 
• the wider system factors such as regulations 
• adaptation over time – more specifically what scope there is for future use. 
(Greenhalgh et al, 2017) 
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The use of this framework allowed us to take a systematic approach to developing interview 
schedules and allowed our findings to be mapped onto key concepts which are highlighted in 
existing literature.  
It is important to note however that we used a general thematic analysis approach where we 
coded the datasets and generated themes and then examined if and how they fitted (or not) 
to the NASSS framework. This allowed additional themes to emerge that might not fit neatly 
into the existing NASSS framework. 
 
Figure 4.2: NASSS Framework (Greenhalgh et al, 2017) 
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4.5 Ethical and Regulatory Considerations 
All personal data was treated as confidential. When participants were recruited to the study, 
they were allocated a unique study number by the research team for reporting purposes. 
During the analysis process, participants were assigned a pseudonym to further ensure they 
were not identifiable. Prior to the commencement of the evaluation, approval was gained 
from necessary regulatory bodies (NHS REC, R&D approval). In accordance of GCP guidelines, 
members of the UoS and GSA research team had received GCP training, research passports 
and disclosure Scotland clearances in place prior to any data collection activities commenced. 
Stroke can affect cognitive ability in some cases and certain participants, dependent on age 
range and capabilities, may have found the length of time needed within some of the activities 
tiring or difficult. For this reason, the research team accommodated these participants by 
providing adequate breaks within sessions. The participants were informed that they were 
welcome to invite a carer or family member along to the activities if they wished for support 
and to facilitate their participation. The research team ensured as much as possible data 
collection activities were arranged at a time and place that is most convenient for the 
individuals involved.  Additionally, participants were informed that they could leave the 
session or end the interview at any time and could choose to not contribute to any activities 
if they felt unable or uncomfortable doing so.  
Participant Information Sheets (PIS) and consent forms clearly outlined how data relating to 
this project was collected, stored and published in accordance to General Data Protection 
Regulations (GDPR, 2018). The consent forms and participant information sheets contained a 
privacy notice to adhere to the new General Data Protection Regulation (GDPR) guidelines. 
To ensure the UoS research team was safeguarding personal data and appropriate 
safeguarding measures being adhered to. It was emphasised throughout the consent process 
that participation is voluntary and withdrawal from the study was permitted at any time 
without reason in accordance to GCP guidelines.  
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5 Mapping the Current AF screening Pathway in NHS Lanarkshire 
 
This section of the report describes and illustrates the existing traditional care pathway and 
patient journey for AF using continuous cardiac monitoring devices such as the Holter monitor 
in three NHS hospital sites in NHS Lanarkshire, Scotland. The resulting mapping can be seen 
in Figure 5.1 but please also refer to the full interactive process mapping document created 
by The Digital Health and Care Institute Design Team (from Glasgow School of Art (GSA). The 
interactive map which captures service insights, opportunities and challenges is available at:  
https://futurehealthandwellbeing.org/atrial-fibrillation (Bruce, 2019) 
5.1 Methods 
 
Qualitative methods were used to capture and understand the current AF screening pathway 
and to identify areas that might present challenges and opportunities for improvement. 
A focus group with stroke liaison nurses (n=6) and four semi-structured interviews stroke 
consultant (n=1), cardiologists (n=2) and cardiac physiologists (n=2) were conducted during 
the initiation stages of the project to understand the existing workflow and pathway. Visual 
mapping tools were also used by the DHI design team to guide the discussions (see Figure 
5.1). These were conducted between May 2018 and July 2019 before the new device and 
service were adopted for this Test of Change in NHS Lanarkshire.  
This data collection activity was audio recorded and transcribed by a professional transcriber 
for analysis and validation. Transcripts from the interviews were initially thematically 
analysed by GSA and UoS. Transcripts and visual outputs from the interviews and focus group 
were analysed using ‘analysis on the wall’ (Sanders and Stappers, 2012) methods in order to 
quickly synthesise the key insights and cluster emerging themes thematically. The findings 
were presented visually to show the insights, service opportunities and challenges along the 
patient pathway.  
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5.2 Findings 
In NHS Lanarkshire, patients are required to wear a Holter monitor (see figure 5.1) for 24, 48 
or 72 hours. The variation is due to inequity of access to prolonged cardiac monitoring for 
stroke patients across the three cardiac physiology departments. After having a stroke, a 
patient may attend the stroke unit via emergency services and may have their initial 
consultation and assessment on a ward setting. They may need to spend a period of time in 
a stroke unit setting for investigation +/- rehabilitation in which case a Holter device would 
will be applied and removed in the hospital setting by the cardiac physiologist (inpatient).  
It was reported during our process mapping that on some occasions, due to limited numbers 
of devices available, the discharge of some patients may be delayed to ensure the patient has 
the device fitted before they leave. Health Care Professionals (HCPs) expressed a view that 
patients who received a Holter monitor as an inpatient do, however, often receive their Holter 
monitor faster (depending on availability of devices) than those who were outpatients.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Holter monitor (cardiac monitoring device) schematic. Used with permission, 
Horan 2019. 
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The Holter monitoring device can also be applied on an outpatient basis (patient is sent home 
with device fitted). For some patients, for whom there is a high suspicion of stroke or TIA, but 
no severe symptoms warranting hospitalisation, they may be referred by their GP to a TIA or 
minor stroke clinic. This first visit will confirm the diagnosis of a stroke and will attempt to 
identify the underlying cause of the stroke. This referral process takes approximately three 
days before a patient consultation within a hospital outpatient setting. At this first visit, if no 
cause is identified or if AF is suspected, patients will be referred to a cardiac outpatient 
department for cardiac monitoring. An appointment will be arranged for the patient within 
3-4 weeks. Patients are required to attend an in-person outpatient cardiac appointment, 
which lasts 10-15 minutes. This appointment will be with a cardiac physiologist who will 
prepare the patients skin (which may involve cleansing the skin and or shaving the skin), fit 
the 3 lead Holter monitor (which involves placing adhesive leads onto the skin and connecting 
the cardiac Holter monitor) and show the patients and or carer how to reapply the adhesive 
leads. Patients will be provided with a contact number (if there are any problems with the 
device) and a patient diary which allows opportunity to keep notes of cardiac symptoms. 
According to interviewees, this can be a very challenging appointment as often patients are 
unsure of the purpose of their appointment resulting in the cardiac physiologist spending 
extra time explaining why they have been referred for cardiac monitoring. 
Although regulatory guidelines highlight the length of time of screening should be a minimum 
of 72 hours, the length of screening often fails to achieve this due to lack of devices and poor 
battery life of current devices. One clinician highlighted how outpatients may have to attend 
hospital once every 24 hours to have the battery changed. This inconvenience was voiced as 
leading both the clinician and patient to request screening for less time despite national 
guidelines for 72 hours of monitoring.  
One main benefit of receiving a Holter monitor via the outpatient approach is the ability for 
patients to live their life within their normal setting (i.e. at home or other setting). Outpatients 
may however be required to attend a midweek hospital appointment for a minimum of three 
visits (one for the application, one for returning the Holter and the final for an explanation of 
the results). Due to the battery life of available devices patients at some sites may be required 
to attend the outpatient department every 24 hours to swap devices. The attendance of these 
appointments was reported as an inconvenience for the patient, with some patients having 
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to request time off work. The patient is then required to arrange the return of the device, 
either themselves or by a carer or relative. As devices are in short supply, if the device is not 
returned, the Cardiac physiologist will spend time chasing the return of the device.  Delay in 
the patient returning the Holter monitor back to hospital or loss of device in hospital due to 
inappropriate return such as out of hours, resulted in additional time being wasted in chasing 
from hospital staff (such as the stroke liaison nurse or cardiac physiologist). Due to a reduced 
number of Holter monitors, this often results in other patients experiencing delays to their 
Holter monitor applications and therefore diagnosis.  
Following the return of the Holter monitor the device is docked, data uploaded, and digital 
report is generated and uploaded to the online system called a Clinical Portal. Senior (Band 6 
and Band 7) Cardiac physiologists analyse the Holter monitor recording using a Space Labs 
analysis programme called Life screen. A patient diary along with a time stamped report of 
the output from the device is reviewed. This review process takes around 20-45 mins 
depending on the length of the screening time. The results of the Holter monitor are 
summarised into a written report. This report may be uploaded to a clinical portal or a hard 
copy is forwarded to relevant recipients such as the stroke clinician or GP. Either of these 
health professionals will then liaise with the patient to decide on the treatment pathway. In 
addition to this process, a hard copy of the report may be sent via internal mail to the patients 
General Practitioner (GP). Depending on accessibility, the digital report may also be delivered 
by hand to the stroke consultant by the stroke consultants secretary. Upon review of the 
report, a diagnosis of AF may be confirmed, and long-term management of the condition can 
be commenced including education, medication and support.   
Some healthcare professionals highlighted that lack of staff can lead to delays in this analysis 
process.  They also highlighted that the lack of staff and resulting high workload within this 
speciality has resulted in the delay of results for patients. Lack of cardiac physiologists is 
highlighted in recent literature (BHF, 2018) which recommends that additional funding is 
provided to increase HCPs in this area (Scottish Government, 2019).  Problems associated 
with inaccessibility or lack of awareness of the computer programme to access of the report 
and loss of paper copies sometimes required secretaries to manually check the status of the 
analysis process to ensure the quality care for the patient. 
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It was reported that the current Holter monitor used in the screening of AF is associated with 
some inconvenience or discomfort for patients. For example, the bulkiness of the Holter 
monitor was reported as hard to disguise under normal clothing especially in clothes worn in 
warmer weather. This can cause some patients to feel distress and has resulted in patients 
having to disclose personal information relating to their screening due to relatives or friends 
questioning the reason for wearing such a device. It was also reported that some patients 
have expressed sensitivity to the patches and feeling uncomfortable as a result of wearing 
the device in warmer weather. The Holter Monitor should be removed when showering or 
bathing and reapplied when this activity of daily life was finished. This routine daily task can 
result in shorts periods of time when the continuous recording is interrupted and poor-quality 
recording is often experienced after reapplication. 
In summary a number of challenges exist when using existing Holter monitoring. AF can 
sometimes have no symptoms (asymptomatic), which can mean the person is not aware of 
having AF. Identifying AF can therefore be difficult as AF does not always present with 
symptoms and episodes of AF can be intermittent. Therefore, longer screening periods may 
be needed to detect AF in some individuals than is currently available via the Holter monitors. 
The current Holter monitors require the patient to attend a hospital or clinic in person on at 
least two occasions to have the device fitted and removed. This can be resource intensive for 
the hospital staff but also inconvenient to the patient. An additional burden is that the patient 
cannot shower with the current Holter device on which can have a significant impact on 
patient experience. Finally, it was recognised that there is currently a national shortage of 
cardiac physiologists who undertake the device fitting and interpretation of the device data 
(BHF, 2018). The current mapping stage suggests that the use of alternative technology could 
improve the timeliness of screening and quality of screening for AF in this population. 
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Figure 5.1 Existing Service Model and Pathway (Bruce et al, 2019) 
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6 A New Technology Enabled Care Pathway for AF screening in NHS Lanarkshire 
 
This chapter of the report presents the new AF pathway (innovative technology enabled service) that 
was deployed in NHS Lanarkshire as a Test of Change during 2019. UoS along with the DHI design team 
(GSA) mapped the new pathway using interview data in order to highlight areas along the pathway that 
might introduce time or cost savings (compared to existing pathway presented in Chapter 5) if the new 
service was introduced, or other perceived benefits to either the clinician or the patients. 
6.1 Procurement of new AF screening Technology in NHS Lanarkshire 
 
Together with NHS Lanarkshire we undertook a national procurement exercise looking for commercially 
available products. This was done through the national procurement system with NSS (National Services 
Scotland) procurement for NHS Scotland to ensure that any devices (and associated services) selected 
would be readily available for scaling. The UoS and Napier research team, along with NHS Lanarkshire 
agreed a set of criteria that the device must conform to in order to be issued a Prior Identification Notice 
(PIN) notice for calls for bids through national procurement services to be the test of change service 
provider for the new AF screening technology (see Table 6.1). 
Seven companies submitted bids for this project, however, only two companies met the procurement 
criteria and both were selected for a pilot with n=10 patients. This was decided so that different form 
factors and devices could be compared for acceptability and usability within the clinical context prior 
to full implementation and final evaluation. One of the devices selected was reported to cause serious 
or significant skin irritation in four out of the ten patients that the device was applied to and therefore 
it was decided quickly not to progress with the full evaluation of this device.  
The device that was selected for the full roll out in NHS Lanarkshire was the BARDY CAM™ ™ by Bardy 
Diagnostics (https://www.bardydx.com/) (see Figure 6.1). The CAM is designed to be placed along the 
sternum—over the heart— to optimize P-wave signal capture. The idea is that the result should be 
improved ECG resolution, providing more information about the heart rhythm which may lead to more 
clinically actionable diagnoses. The distributor for this device during the GoLive for this implementation 
was a company called Dot Medical (http://www.dot-medical.com/).  
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The BARDY CAM™ (at the time of testing) allowed 7 days of continuous monitoring and therefore 2 
devices per patient were purchased to allow for 14 days of continuous monitoring. The company also 
provide a managed service around this device which included (i) initial training of staff, (ii) software for 
uploading the data from the device, and (iii) a reporting service conducted by the company rather than 
the NHS. The data from the devices is used to generate event-tagged reports. These reports can be 
generated within the NHS context by trained staff but the company also provide a service where they 
have technicians and a system for generating the reports and providing these to the HCPs at an 
additional cost. This device was selected as a demonstrator to test how this and similar new wearable 
and commercially available AF monitoring devices might be adopted. This also allowed them to test 
how the service could benefit from moving some of the reporting to outside of the NHS. 
Criteria category   Definition/ criteria of Assessment  
CE marking?  If a device is marked with the initials CE (Conformité Européene), this ensures the device confirms 
to European standards of safety. Such a requirement is essential for use within the NHS and for use 
within the public population (GOV, 2018).  
Recording time. Recording time should be documented. For purposes of this study 72 hours of continuous recording 
time is required.  
Available for home use? Available to be purchased and used within the home environment. Not requiring in hospital stay.  
Evidence of ease of use? Evidence of feedback regarding the ease of using the device (application, charging, reapplying etc).  
Evidence of patient comfort? Evidence of feedback regarding the comfort of the device (specifically no evidence of skin irritation 
when wearing the device).  Evidence of being user friendly.  
Specificity/ sensitivity Evidence of the ability of the device to identify AF.  
Single/multi-use? Evidence on whether the device is single or multipurpose use.  
Both have advantages:  
Single use: infection control implications reduced.  
Multi use: reusable devices can be used on more than one patient 
Easy to clean? 
Cost? Price is documented.  
Control of data? Documented evidence of:  
Who owns the data? 
What data is collected? 
Where is the data sent and stored? 
When is the data deleted? 
How is the data transferred and reported? 
Battery  Chargeable?     Battery length?  
Table 6.1 Selection Criteria for Procurement of AF device for Test of Change in NHS Lanarkshire 
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Fig 6.1: Used with permission. BARDY CAM™ device 
 
6.2 The new AF service pathway 
 
In order to understand the new AF pathway incorporating the new device and 14-day outpatient 
monitoring being tested in NHS Lanarkshire, the new pathway was mapped with the health 
professionals involved in this pathway. Two seven-day BARDY CAM™ devices were provided to N=64 
patients in NHS Lanarkshire to allow up to 14 days of continuous monitoring data (swapped on day 8). 
The first device was issued and applied to the patients during a clinical visit by the stroke nurse. The 
second device was applied during a second visit on day 8 (where the first device was then docked to 
allow uploading of the seven days of data). The data was uploaded for the second device (second seven 
days of monitoring) when the device was posted back by the patient to the hospital site. The BARDY 
CAM™ software provided a report which the lead clinician could review for diagnosis producing a total 
of 128 reports (64 patients with two set of seven days of data on each device). An example report 
produced by the company can be found in Figure 6.2. 
For this roll out, a subset of the reports (28 reports) were also analysed by a subcontracted NHS cardiac 
physiologist. This would allow us to compare a potentially more cost-effective off-site analysis of the 
reports by the company and compare the analysis done (cases found and time taken) by both the 
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commercially available system and the off-site but NHS based cardiac physiologist. The results from this 
comparison are presented in Chapters 7 and 8.  
Figure 6.3 shows the visual mapping for the new pathway once this device and reporting system (the 
service) was introduced. We focused on three main themes or strands for this analysis – Patient 
experience, Clinical experience, and Implementation of the new service in the NHS setting. This can be 
compared to Figure 3.1 to identify potential points in the pathway that have been affected by the 
introduction of the new service (reduced or additional time or costs for example). Please refer to 
Chapter 7 for the origin of these experience and implementer quotes. 
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Figure 6.3 the visual mapping for the new pathway 
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7 FINDINGS 
 
7.1 Summary of Quantitative Results 
Sixty-four (64) participants (patients) wore the BARDY CAM™ device from July-October 2019 
meaning that during this test of change NHS Lanarkshire increased the length of time of 
continuous AF monitoring (5-14 days [average 12.09 days]) for 64 patients. Four individuals 
(out of 64) had AF diagnosed (6.25%) during this time. All these individuals were commenced 
on a blood thinning drug as they were considered to be at a high risk of having a further 
stroke. Two individuals had another unknown and clinically significant heart arrhythmia 
diagnosed whilst wearing the BARDY CAM™ device and their treatment and care pathway 
changed due to this finding.  
Some participants noted skin tolerance issues (n=9) which included the device falling off 
(n=2), one person reapplied with skin tape; skin redness (n=4) and itch (n=1) delicate skin 
(n=1); broken skin (n-1). The one individual who was noted to have broken skin was also noted 
to have an allergy to nickel, the device does not include nickel, however the skin preparation 
was noted to include nickel, but this was not noted until further investigation by stroke liaison 
nurses.  
7.1.1 Costs (£) 
The initial outlay costs for the test of change which included the device and the service around 
it (the reporting done by the company) are reported here for descriptive purposes only. A full 
cost-benefit analysis will not be conducted here but is likely to be something that some 
people would look for longer term. However, throughout this chapter we have sought to 
capture some of the additional perceived costs and benefits to both the clinician’s and 
patients which could potentially be used for a fuller cost benefit analysis in future work. As a 
cost analysis was not the purpose of this chapter, please note, additional costs related to HCP 
involvement (such as specialist nurse over time, additional visits, travel costs) were not 
recorded.  See figure 7.1. 
46 
 
 
Figure 7.1. Overview of costs associated with project. 
7.2 Qualitative Findings Overview 
As described in Chapter 4, interviews were conducted with a small but purposive sample of 
patients (n=8 Patients and n=1 relative) to capture how the patients felt after wearing the 
new device and experiencing the new pathway. Six (out of the 8) patient participants were 
male, two were female and the one relative was female.  In addition, interviews were 
conducted throughout the project (before [n=5 implementers, n=11 HCPs] during [n=2 
implementors, n=9 HCPs], and after [n=1 implementor, n=4 HCPs]) to capture expectations of 
the new service, experiences of the new pathway (Stroke nurses and clinicians) to identify 
potential barriers and facilitators to the adoption and uptake of this kind of service within an 
NHS setting.    
 
Patient Experience Condition, Technology, Value. 
 
Clinicians Experience Condition, Technology (device and 
reporting), Value (Accuracy and 
Trust). 
 
Implementation Procurement, Planning, Participation, 
Training, Resources. 
Table 7.1 Overview of key themes 
BARDY CAM™ (per device) = £117. 
120 devices were purchased (2 devices per patient for 8 days plus 7 days) = 60 patients. 
Devices Total Cost = £14,040. 
Docking station: £300 (per station) (n=1). 
Report generated by the company (including VAT) = £34 per report. 
120 reports (60 patients) = £4,080 
Reports secondary analysis within NHS = £2,208 (6 days’ work) (Included training time, 
ICT set up and output 28 reports).  
Total = £20,628 
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7.3 Patient Acceptance and Experiences                                    
 
Eight patients and one family member were interviewed to capture experiences of wearing 
the new device and the overall AF screening experience from start to finish. The important 
issues (themes) that emerged from the patient perspective will be presented in the following 
summary with supporting quotes. 
7.3.1 Condition (diagnosis, fear, identity)                                            
 
All patients (n=8) explained their experience of their stroke and the feelings associated with 
their experience in relation to the condition itself. For example: 
 
‘I had come down the stairs in the morning and I went into the kitchen and I just felt 
my whole body going to the floor and I couldn’t move, I tried to move, I couldn’t move 
my body at all, it was quite frightening, you know.’(Pt006) 
 
The physical impact of the stroke varied between participants, with one explaining her 
difficulty communicating to her daughter and health care professionals. 
 
‘…they were speaking to me and I knew the answers but I just couldn’t get the answer 
out… I was quite concerned because I kept looking at my daughter and my son and 
tried to tell them what it was and it really got me quite upset.’ (Pt 002) 
 
Others described the loss of physical sensation, collapse, and the accompanied fear they 
experienced. One of the participants had no recollection of his stroke and relied on his 
relative’s explanation of events as this interaction illustrates:  
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(Participant 008).  ‘He was lying on side and I knew right away that there was 
something wrong.  So I started to talk to him and he just made this noise and I got him 
out of the bed and onto the floor….. So I got him down and I put the phone on loud 
speaker and I dialled the ambulance and he was really out of it.  The ambulance 
stopped at the gate and he started to come round a bit, by the time they came in I had 
him up’.  
 ‘I can’t remember any of this’ (Pt008, relative) 
 
The psychological impact of having a stroke was described by one participant: 
 
‘My grandson brought me magazines in and I couldn’t read a line, I just kept going 
back over and back over the reading and my grandson put the wee cards in the 
television.  So I was sitting trying to concentrate on what was getting said on the 
television, because I just felt I was isolated you know, and everyone was different.  But 
I was trying to get myself a bit of something for me, you know, I wanted to do 
something – I’m just trying to think how I was feeling you know.  It was a harrowing 
time – I never had anything like that in my life if was quite unknown in my body, you 
know what I was going through and yet it was me that was having to go through it 
you know.’(Pt006) 
 
Two patients described attending their GP prior to their stroke and not necessarily receiving 
a clear diagnosis at the time which led to some additional confusion and fear. For example: 
 
‘When I got to see the doctor and I told him about the sore head and my fingers weren’t 
working properly and he said, “how are they now” and I said, “they’re working fine 
now.” So he lost interest in that part, he examined my ears, told me I had an ear 
infection, which I didn’t know anything about and gave me antibiotics’ (Pt009) 
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As well as the physical and psychological impact of experiencing a stroke, other impacts such 
as housing adaptions, impact on work and loss of independence were also discussed by 
patients and the relative. For example: 
 
‘He was in for two weeks basically because we had renovated the bathroom to get him 
home and I had to change it all because we couldn’t have got him in the bathroom.  So 
that took the time before I could get him out and it’s me that said it needed done, but 
it was worth it’. (Relative 008) (Relative) 
 
‘I had to take the week off work ..… because I work up on scaffold, so I couldn’t go to 
work, they said, “right you can’t go on scaffold.” (Pt004) 
 
Experience regarding the NHS was voiced as being overall positive, with one participant 
describing his experience as; ‘I got first class treatment, first class’ (Pt 005). One relative 
described being overall being pleased with the care, however expressed that concerns when 
in an emergency setting they didn’t feel that they were taken seriously. Another participant 
expressed disappointment with the lack of communication within the hospital ward setting.  
 
‘I think it was because of me I didn’t know what I was really doing, but there was not 
much encouragement being brought [referring to a ward setting], only that it was the 
young nurse that would come over and ask things you know.  But the older, the senior 
ones I just felt there was a lack of communication, maybe not wanting to respond to 
somebody with a stroke, I’m not sure.  You know I felt that could really be something 
done, yeah.’ (Pt006) 
 
7.3.2 Recruitment and Participation   
Most participants were pleased to hear about the evaluation of the device they were wearing, 
however one participant (a relative) had concerns that this might mean that something was 
wrong with their relative, this is reflected by the below quote.  
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‘I was a wee bit concerned that there was maybe something wrong, that he had been 
chosen for it, but when I spoke to the male nurse that came in, he said, “no it’s for 
research, basically it’s a research programme,” I said, “yes, because if there was 
something wrong I would like to know about it,” he said, “you would know about it”…’ 
(Pt008) (Relative). 
 
After initial approach, the stroke liaison nurse contacted the patient to arrange a suitable time 
to visit their home. The standard and quality of explanations was considered to be good by 
all, no participants voiced difficulty in understanding or poor explanation from the stroke 
liaison nurses. Visiting at home appeared for most to be convenient and valued, this is 
supported by the below quote.  
 
‘[He] hates hospitals, when we go to them it’s a screaming match, but I think the fact 
that he came to the house and it was just us, you know it was easier.  I think maybe a 
younger person getting it fitted would be alright in a hospital, but he took the time to 
explain everything out.  Whereas in the hospital they usually, that’s it and then you go 
and this is what you do and hand you a bit of paper, but he explained it right from the 
word go to the end of it.’ (Pt 008) (Relative). 
 
Although most patients were happy to be recruited into this project, one HCP highlighted that 
one patient declined to participate due to the requirement of wearing a non-underwired bra 
for the duration of the project.   
 
‘I think the benefits are obviously diagnostic getting a diagnosis, I think the 
disadvantages are, I think basically very individual depending on the potential 
participant of wearing it, I think it's their choice and I think that's probably that the 
main disadvantage, as particularly for female patients the fact of not being able to 
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wear an underwired bra but for myself in relation to the overview of the device it’s of 
more value than it is non-value.’ HCP004 
 
‘And has there been any patients that have declined to wear the device?’ 
 
‘I’ve had one lady that, basically my process of introducing the device is explaining the 
purpose, that’s it a diagnostic test, it’s a unique system that’s advantageous for our 
team to be able to apply it, have it analysed and then look at the treatment, so the 
whole process. And again I focus it on, the purpose of it is for the early diagnosis to 
reduce the risk of that individual person having another stroke. So I explained all that 
side of it first and then it was a lady, so I then explained to her where the device was 
applied and then I asked her is that an underwire bra, something that you wear on a 
daily basis and she said yes. I said in relation to wearing an underwire bra and the 
device, I explained that can be a bit of interference so to optimise the benefits we 
would recommend that you wear a sports bra. She had a function at the weekend and 
didn't want to wear it, I offered to delay applying it but for her personally and for 
herself image she just was not prepared to wear an underwire bra for the duration 
that was required, so she declined for that reason.’ (HCP004). 
 
7.4 Technology 
 
Two BARDY CAM™ devices were applied for seven days each. One BARDY CAM™ was applied 
on Day 1 by the nurse in the home. Prior to its application, the skin was shaved (if required) 
and cleansed. On day 8, the first BARDY CAM™ device was removed, the patient had an 
opportunity for a shower, the skin was shaved (if needed) and cleansed and the second device 
was applied and worn for seven days. The second BARDY CAM™ device was removed by the 
patient or relative and returned directly to the hospital, either by the relative or by post.  
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7.4.1 Application of the device by Stroke Liaison Nurse 
 
Both BARDY CAM™ devices were applied by the stroke liaison nurses in the homes of the 
participants, this is reflected by the below quote;   
‘It really was quite straight forward, I had a phone call and a letter in to say when to 
go and at time when you leave hospital. Somebody came out and it just stick on, it took 
about quarter of an hour, twenty minutes all in and that was it.  I had to keep it on for 
a week and then change it to another one which was the same.’ (Pt004).  
‘The stroke nurse came in, after the first seven days she came into the hospital took 
the first one off and put the second one on for me, and then she come in the following 
week and did the same thing. ‘(Pt002).  
All participants interviewed stated this process worked well.  
Although all patients had the device applied by a nurse, some patients expressed concern that 
if applying the device themselves, they may have they may have had difficulty (Pt001; Pt003) 
and would have required clear instructions if completing it independently (Pt001) whilst one 
relative suggested they would need to apply the BARDY CAM™ , as it may be too difficult for 
their relative. Another expressed they were happy for the support but felt able to put another 
device on, this is reflected by the below quote.  
‘Well I was pleased that they put it on initially but I think it’s a device that you could 
put on yourself because it’s very, very simple and even taking it off it’s just a matter of 
taking it off and just making sure that your skins alright’ (Pt003). 
7.4.2 Appearance of the device 
 
Overall feedback regarding the appearance of the device was positive, participants described 
the device as ‘Unobtrusive’ (Pt 001); ‘more than fit for purpose’ (Pt004), ‘nice and neat and 
small and it wasn’t an inconvenience to me, I thought it was ideal’ (Pt 003). ‘Forgetting about 
it’ was a theme expressed by five participants (001; 002; 005; 007; 009), this is supported by 
the below quotes.  
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 Well it was pretty unobtrusive really, most of the time you forgot it was there’ (Pt 001).  
 ‘I don’t even know it’s there dear to tell you the truth.’ (Pt 005). 
 ‘Yeah, it was quite comfortable.  You didn’t know you had it on’ (Pt007).  
 
 ‘It was completely painless, I didn’t even notice it, even in the shower and the only time 
it ever became a problem was when I was drying myself, because you forget it’s there.’ 
(Pt009). 
 
However, one participant noted that although mostly forgetting it was there, the button 
placement at the front made him conscious of wearing the device at times. This is supported 
by the below quote.  
 
‘Aye, as I say you forgot it was there, but again that’s the only thing I would say is if 
you leaned against something you were conscious of especially the button being in the 
front’(Pt001). 
 
7.4.3 Comfort of the device 
 
Three participants clearly articulated there was no effect on skin. Although mainly positive 
feedback was captured, one participant noted a skin irritation, describing the first day wearing 
the BARDY CAM™ device as ‘slightly itchy’, which was considered as mainly being due to the 
adhesive from the device (Pt009).  Discomfort and difficulties were expressed when removing 
the BARDY CAM™. One relative described the skin as being red after removal, this is 
supported by the below quote.  
 
‘Because after it came off, I thought I’d took the skin off all of it, but I hadn’t it was just 
a red mark where it had been sitting, but then again it would need to be like that 
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because it was underneath your clothes all the time, you know if it didn’t like a plaster 
if would have been off in a couple of days’. (Pt008) (Relative). 
 
The participant related to the above relative described the process of the removal of the 
device as being ‘sore coming off’ (Pt007), another participant described it as rather ‘painful’ 
(Pt009), this is further supported by the below quote.  
 
‘Aye, well the chap that did the fitting took it off, but he also had some fluid or other 
that he dabbed on it and actually came away not too bad.  But when I did it, I had an 
awful time, I had to get a knife, I couldn’t pull it because my skin was coming out, right 
and I didn’t want to [cause] myself any damage, so I got a fileting knife from the 
kitchen and Vaseline and just slowly just sat and worked it down.  It was rather painful 
coming off, that was the second one.’ (Pt 009). 
 
The cause of discomfort appeared to stem from the adhesive, with some patients expressing 
that it was too sticky. However, one participant expressed that their second BARDY CAM™ 
lost its adhesiveness. This is reflected in the below quote.  
 
‘I had to keep it on for a week and then change it to another one which was the same… 
it stayed on, it started to lose its stickiness after about four days, come day six, day 
seven, well on me anyway it had moved a bit, but it was still in place but it was 
definitely losing its stickiness.  But other than that it was brilliant.’ (Pt004).  
 
Other feedback focused on personal washing. One participant expressed no difficulty with 
personal washing, this is reflected by the below quote.  
 
‘To be honest, once the nurse came to the house and put it [on]… we had to shave a 
little bit of hair beside my breastbone, once it was on, I could shower no problem, it 
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didn’t interfere with my clothing, it didn’t interfere with… it was actually ok, no 
problems at all with it.’ (Pt003).  
 
However, one participant expressed altering her personal washing and two participants 
explained how they placed Clingfilm over the device before showering.  
 
‘Well if you’re getting a bath, you couldn’t really get washed the way you normally did 
in your bath, but that didn’t bother me because I knew it was something that I wanted 
help with.  It helps yourself and the doctors and surgeons for other people, and it 
wasn’t a bother really, I just did what I did.  It didn’t worry me, to help you know.’ 
(Pt006). 
 
 ‘Yeah you actually forgot you had it on, because where it was sitting it was really very 
comfortable, you didn’t have any problems with it at all.  The only thing when I was 
showering I covered it in Clingfilm just so it wouldn’t get wet. ‘(Pt002). 
 
To gain a clearer reading from the device, participants are requested to not wear an 
underwired bra whilst wearing the device. Although, some participants expressed to 
healthcare professionals (see HCP results) their refusal to participate due to this reason, only 
one participant from those interviewed expressed purchasing alternative underwear, but 
stated this wasn’t an inconvenience, this is supported by the below quote.  
 
 ‘The only thing that they did say to me was, I wear underwire bras, so they had told 
me don’t wear underwire bras with it because the wire could affect the monitor.   But 
that was the only issue and that wasn’t a problem, I just got out and got other ones. 
‘(Pt002).  
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7.4.4 Returning the device    
 
Most participants wore two devices over a 14-day period. The first device which was worn on 
day 1 until day 8, was removed and collected by the stroke liaison nurse on day 8. The second 
device was removed by the patient or their relative on day 14 and was posted back or 
returned back in person, depending on preference. Participants were provided with a 
stamped and addressed envelope on day 8 by the stroke liaison nurse. Most participants 
expressed they were able to post the second device back via post and did not verbalise any 
difficulty with this process. One participant expressed preference that his daughter would 
return the device in person (Pt005).  
 
7.4.5 Comparison with other cardiac monitoring devices   
  
Some participants had worn other cardiac monitoring devices in the past such as Holter 
monitors and so were able to draw comparisons between the two devices. One participant 
expressed a preference to wear the BARDY CAM™ device compared to wearing a Holter 
monitor, but only if the adhesive was altered, this is reflected by the below quote.  
 
 Interviewer: ‘So if you were to compare the two devices, which one do you think you 
would like to have again if you had to have it again?’ 
 ‘The most recent one, if they do something with the adhesive.’ (Pt009). 
This participant also stated that when wearing the Holter monitor, the showering was 
restricted, this reflects the importance of the ability to shower with a device, and is reflected 
by this quote;  
‘For the three day one I stopped showering, for the seven day [Holter] one, I said, “look 
I’m not wearing it unless I can take a shower’ (Pt009).  
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Another two participants explained their experiences of wearing a Holter monitor in 
comparison to the BARDY CAM™ device.  
 
‘They gave me some [adhesive patches] just in case they came off, “what if it comes 
off,” “just put it the same place, make sure the same cable goes in,” they were all 
colour coded anyway so it’s. Again a couple of them came off, when you go for a 
shower and that but apart from that it was a pain compared to the one that you just 
stick in the middle.  The difference is unbelievable because as I say that one is pretty 
unobtrusive, the things with all the stickers and the wires all over the place, they were 
just a pain.’ (Pt001). 
‘I would recommend it, I would say if anybody was given an option of wearing the three 
prong ones or wearing this, I would take the sticky middle of your chest one every time.  
It’s easy, it’s stuck on and that’s it.  I would reckon if you were just doing an ordinary 
desk job or something you probably wouldn’t have any problems with it staying on for 
the full seven days.  I think it was me being out in the kind of work that I do that it 
started to lose its stickiness after the five days.  Aye it was very easy to wear, the fact 
that you can come in and get a shower with it on and be normal was magic.’(Pt004). 
‘I think this is a better device because the other ones some of them are quite bulky and 
that and a lot of people don’t want to wear them.  But I think if you were offering this 
to people I’m sure they would be very willing to use it.  As is say, I know I would anyway 
‘(Pt002) 
Comfort and ease of use were important aspects of the device which were reflected from 
some interviews. Although, they stated they trusted the device, when asked, one participant 
and their relative joked that they were concerned that someone was listening or filming them. 
They expressed their two-and-a-half-year-old granddaughter thought wearing the device was 
funny, this potentially reflects lack of embarrassment of wearing the device in front of family 
members. The below quote may indicate a lack of trust with the device or healthcare 
providers. 
58 
 
 ‘I was a bit worried they were maybe filming us, [laughing] somebody’s listening to us 
here [laughing].’ (Pt008).  
 ‘Our granddaughter] was only two and half then, [she] was like this, what is this, and 
she said, “is that an eye” she used to dance in front of you, “are you watching me?”  
She thought it was hilarious. (Pt007). 
Cardiac physiologists commented on the form of the new AF devices: 
“I like the idea of a plaster, that would be better for the patient’s comfort 
(they can have shower, they can run with it), much better for them.” 
(HCP008). 
7.5 Perceived Value (reported by Patients) 
 
Although some participants expressed that their participation was to be a help to others, 
some expressed value to their own health if Atrial Fibrillation was identified. This is reflected 
in the below quotes.  
 
 ‘It would be helpful because if it had recorded any faults or that, that would have been 
helpful at the time, but it recorded nothing untoward. ‘(Pt009). 
 
‘Well I think it’s helped a lot because as I say I was able to find out exactly what it was, 
what was happening to me…. if I hadn’t had that device on I wouldn’t have had a clue 
of what it was.  … if you go to the doctor you maybe taking any of these things at the 
time and they don’t know what’s happening with you.  I think it will be a very useful 
thing to have’ (Pt 002). 
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Having the stroke liaison nurse team as a support was reassuring to some participants, with 
another stating:  
‘To be honest the [hospital] has been wonderful, they really have.’ (Pt008).  
‘No, I can’t really think of anything, I’m just so grateful for like my stroke nurses coming 
in, you know the girl that came in, even in [to the] ward you know it was really a place 
where people, nurses do help you know and it’s a place – they’re needed’ (Pt006). 
 
Overall, patients considered wearing the device as a positive event, often referring to it as an 
experience which would be of help to others, this is supported by the below quotes.  
 
 ‘Yeah, my experience of using the device, it was no problem it didn’t interfere with my 
everyday life, yeah no problems.’   (Pt003). 
 ‘No, no I’m just quite happy that I got the chance to use the device and it helped with 
my diagnosis that gave me some reassurance that I was on the mend.’ (Pt003).  
 ‘If it’s going to help anybody, I’m 100% for it.’ (Pt005). 
 
Summary 
Sixty-four patients wore the BARDY CAM™ for 5-14 days (average 12.09 days) in a new 
managed AF screening service. Eight patients and one relative were interviewed in person or 
over the phone to explain their experiences of the new service and technology. Feedback 
from patients was also relayed from interviews with health care professionals. Patient 
experiences of the new screening service were overall noted to be positive. The results 
indicate that patients appeared to value the technology within the service, however some 
comfort and skin sensitivity issues were noted to impact acceptability and are recommended 
to be resolved. Some patients also altered aspects of their daily life (such as showering) when 
wearing these devices. Overall, patients appeared accepting of the new service and value its 
potential improvements to the NHS.  
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8 FINDINGS: Implementation 
 
 
This chapter will focus on the findings from the perspective of the health and care 
professionals involved (stroke team) and also those involved in the wider implementation of 
the complete service (e.g. from procurement, to project management, to the reporting 
service). Key themes emerging from the interview data will be highlighted with the support 
of quotes from the interviews to highlight key barriers and facilitators to the success of the 
roll out of the new device in NHS Lanarkshire.  
It is important to note that different individuals were involved at various time points during 
this implementation process, and therefore their perspective may be influenced by their role 
at this time. 
8.1 Procurement, Device Selection, and Piloting 
Initial stages examining the adoption of a new AF monitoring service into the health service 
involved the procurement process. This involved collaborations from academics, an 
innovation centre and local NHS teams meeting for ‘two or three half days’ PF001 and 
included ‘read[ing] through all the leaflets and kind of scor[ing] them...’ (PF001).  
While national guidelines should clearly inform device selection, local expertise and practices 
may also determine what properties and behaviours the device should and should not have. 
Therefore, a set of inclusion and exclusion criteria for AF device selection was established by 
a team consisting of 2 digital health experts from University of Strathclyde (LM and MML), an 
AF academic expert from Napier University (LN), and 2 clinical stroke care experts (MB and 
KB) from NHS Lanarkshire (Table 6.1). Further input on coordinating and facilitating the 
procurement process guided the PIN notification process, this was provided by a procurement 
expert at the National Services Scotland (NSS). It was agreed that the acceptability, usability 
and feasibility of these devices should be more closely assessed by both patients and 
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professionals during a pilot phase and within the main implementation and roll out of any 
selected device(s). 
This collaborative partnership process was unique and essential in order to fully capture 
barriers and facilitators that exist even as early as identifying what devices and/or companies 
fulfil not only the clinical requirements but also governance requirements such as where the 
data is stored (data governance) as well as what devices might be acceptable nationally, and 
also what type of data and reporting the device and company can provide in the context of 
both the service delivery itself but also in terms of what data would be available for ongoing 
evaluation of that device and surrounding processes.  
A prior information notice (PIN) was advertised online on the 27th February 2018 which 
commenced the first stage of procurement. Following the closing date on the 9th March 2018, 
members of the collaborative team (JB; MB; KB and LM) met to review and consider the 
applications (15th March 2018). Although no contract was formed at that time point with 
either of the companies, both agreed to provide initial training, and made two devices 
available for a trial period with no associated costs (July-Aug 2018). This initial pilot was 
focused on evaluating the process of using the devices (patient and clinician perspective). 
Health professionals valued this opportunity to pilot devices within their work processes and 
with their intended patients’ groups: 
‘it’s one of the more interesting parts of the study … you could easily as a health board 
have gone out and bought [the device]’ (PM001)  
Referring to one of the devices available, one HCP noted the difference between devices that 
are marketed more towards a consumer market and those that are still marketing to the NHS 
as the primary buyer. 
‘their packaging, they’re marketing it very well, it’s very consumery, buy if off the shelf, 
buy it yourself, health monitor.  It looks like a heart- it’s a cool a bit of kit, it’s got a 
good branding around it’ (PF003).  
62 
 
The training day for one of the selected companies - BARDY CAM™ (Device 1) took place in 
May 2018. This training day introduced the device to relevant healthcare professionals. They 
had the opportunity to practice applying the devices and giving the individuals further 
information about how the device works, how it may impact their daily activities and advice 
regarding returning the device. Feedback throughout this day was overall positive.  University 
of Strathclyde (SH) and Napier University (LN) were present for this training day and 
informally captured qualitative feedback. Positive feedback was given to the clinician from 
patients and healthcare staff regarding the training and device. Prior to two interviews being 
led by GSA, some staff also informally provided positive feedback about the training day and 
device. 
The product was initially piloted on a healthcare professional (n=1) and a selection of 
inpatients and outpatients (n=9).  These volunteers wore the devices for a seven-day period. 
It was planned that following the return of the devices, analysis would be completed by 
relevant cardiac physiologists. However, difficulty setting up the software on the NHS 
computers delayed analysis of the device reports by these staff members. To ensure analysis 
reports did not delay patient treatment, this process was outsourced entirely to the company 
(BARDY CAM™) for the pilot to reduce the workload on cardiac physiologist.  
The training of Device 2 took place on 29th August 2018 with 5 patients being fitted with the 
device on the same day. After a few days however, the clinicians stopped the pilot early due 
to several concerns from both patients and clinicians about the comfort and clinical suitability 
of the CE marked device (primarily due to the comfort and wear-ability of the device).  
Significant skin irritation issues related to the second device that was piloted led to removal 
of this device from the test of change. The amount of evidence and the range of populations 
that have tested each device is of significant importance for the HCPs. Many new devices are 
marketed well but there is a lack of evidence for their use with different patient groups in a 
variety of contexts. It is important that evidence-based judgments can be made about the 
true efficacy of the device for any particular group or setting.  
‘But the problem, and I think we were possibly slightly naive was, they had never put 
it on frail people. It had always gone on athletes etc. before, and I think that was the 
problem.  It was a completely different cohort of patients that we’re looking at, who 
63 
 
potentially didn’t have the mobility or the body mass that they had been using it on 
before.’ (PF1) 
Clinical experts decided to proceed therefore with the implementation of device one - the 
BARDY CAM™ device into their service.  
It is likely in a market with many new emerging devices that procurement checklists will have 
to be updated to allow newer more innovative devices and smaller companies onto the 
market. This will require a step change away from larger corporations with legacy NHS 
contracts towards more innovative and adaptive procurement policies and practices. Not all 
NHS boards will be equally equipped to deal with this and therefore checklist and guidelines 
for procurement will be a necessity moving forward in this area. 
8.2 Distributing, applying, and returning the devices 
 
8.2.1 Device distribution 
In the initial stages of the research project, a cardiac physiologist was planning to be involved 
in the application, collection, upload and analysis of the AF monitoring data. Due to the 
limited number of cardiac physiologists, stroke liaison nurses led in the application, collection 
and upload of the BARDY CAM™ devices for the test of change and analysis was outsourced 
to a company. Although stroke liaison nurses were not previously directly involved in the care 
pathway for individuals who require screening for AF, involvement in this project led to the 
adoption of new roles which required additional training, additional planning and additional 
resources (travel visits to the participants homes).  
Length of time of application of the first device varied from 4 – 15 mins (with a mean 
application time of 6.15 mins). Length of time of the application of the second device varied 
between 3-15 mins (with a mean application time of 5.47 mins). Two main challenges were 
noted by stroke liaison nurses, the first was related to approaching the participant in the first 
visit and this may have impacted the length of time of this visit, which may be related to the 
application, this is outlined in the below quote.  
‘…it just meant that the second visit lasted an hour, which is what we’d scheduled for, 
it could potentially last two hours. Because you would be going into the first visit and 
64 
 
then we kind of tweaked it around whether you apply the device and then do the visit 
or do the visit and then apply the device.  Because you’ve got to bear in mind these 
people have been at their work on Tuesday, had a massive stroke, they go home two 
weeks later, you’re going in three days later after they’ve come back home, a 
completely different person….  So any first visit is tricky, but to do that and then say, 
and by the way, we’re going to monitor to make sure you don’t have another one and 
I’m just about to shave your chest and put this on you, and then I’m going to tell you 
all the things you’ve got to do.  That could - made it a difficult visit, extremely difficult.  
So that’s why the length of time that it took for us, was sometimes longer that we 
expected, because of the complexity of the visit.’ PF001  
 
It was anticipated patients would wear the device for 14 days. Reasons for early removal of 
the device included; reason unknown (n=8) (length of recording [days]; 9, 10 [n=2], 12 [n=3] 
13 [n=2]) ; patient preference (n=4) (only wanted to wear one device) (length of recording 
[days]; 7 [n=4]); both devices fell off (patient reported high perspiration) (recording length 
[days]; 11); device failure (n=2) (one device did not record any data and the other snapped in 
half when placing the device) (length of recording [days]; 7); Patient died (n=1) (length of 
recording [days]; 7); bottom half of device came loose (n=1) (length of recording [days]; 11); 
skin issues (n=3) (length of recording [days]; 7 [n=2], 10); unnecessary (n=1) (length of 
recording [days]; 5) and patient going on holiday (n=1) (length of recording [days]; 6).  
There were issues around workload and time needed that were introduced because of delays 
to the project (devices being ordered, and contracts being signed). This meant that a large 
number of patients were identified and lined up ready to receive devices during a period 
(summer). They had to then issue devices quickly over a period of time which might not reflect 
what would happen in routine practice where patients would be identified on a rolling basis. 
‘And that was why the start was so difficult for us. But I think that’s good learning for 
other people in that scheduling in on a dripped basis.  Don’t hold back and then think 
that you can do 20 odds in the one week, which we did.  We probably didn’t need to 
do that, we could just have staggered them, but that’s just not the nature of how we 
do our work.’ PF001 
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8.2.2 Application of the device 
Overall, the feedback relayed from patients to HCP was positive regarding the device itself, 
however, one HCP expressed that a few devices had fallen off early and most significantly, 
one patient had developed a sore whilst wearing the device. These statements are supported 
by the below quotes.  
 
‘We have had a few patients that it’s fallen off before the end of the week. …. in general 
I think the only issue that I felt with patients is a few times that they’ve come off, but 
it was during the really hot period as well. So the people would be perspiring a lot more 
that normal as well, so I don’t know if that has influenced that or not.’ (HCP006). 
 
‘I have had a patient who had a real sore under the actual metal part, but it transpires 
as I was going out the door, because I then couldn’t put the second week on because 
you just couldn’t have put it on top of that. She said that she’d been allergic to nickel 
but I believe that there’s no nickel in it but there will be some other metal thing and 
she must have been allergic to it, so it was a sore, it wasn’t just a rash or anything. So 
there’s been several people with a bit of a rash but nothing that I felt that I couldn’t 
put the Bardy on, they were happy for it to got back on for the second week. But she 
was one I just couldn’t put back on.’(HCP006). 
 
‘It’s been excellent, definitely there’s only the one with the skin contamination I don’t 
know what to call it, that’s the only negative experience, but she actually persevered 
for seven days, although she was scratching the first day, she persevered…but even 
she couldn’t give negative feedback even with the reaction. So I don’t think there’s 
been any negatives at all.’ (HCP003). 
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8.2.3 Returning Devices 
Poor parking in the NHS site car parks led to healthcare professionals having difficulty 
returning the devices to the appropriate hospital for upload.  
 
‘One comment that they’ve made, ….to be plugged in for reading and it’s really difficult 
getting parked here.  So, in terms of practicalities, I think they’re very keen for one of 
those docking devices on the machine, down at [their hospital site] so they can just 
drop it off in their local place and I think that would save quite a lot of time.’ (HCP005). 
 
To address this issue, healthcare professionals organised a docking station at their individual 
hospital sites to allow the devices to be docked and data to be uploaded for analysis. 
 
8.3 Data Analytics and Reporting 
 
One of the significant service changes using the new device was that the company offered a 
service where the reporting is done by their diagnostic team and software off site outside of 
the NHS. This could be a novel model for reporting which could save significant amounts of 
time for NHS staff. It was crucial therefore to examine what challenges and opportunities 
around the analytics and reporting service were present in the interview data with those 
involved. 
8.3.1 Quality of Device Data  
In terms of data gathering the device was not perceived to necessarily be providing a better 
quality of data than the devices currently used by NHS Lothian or Lanarkshire. In 10% of the 
cases dual analysed (3 patients) (i.e. having additional analysis by the cardiac physiologist as 
part of the evaluation) poor quality recordings were noted. This is supported by the below 
statements. 
‘In terms of the outcome itself -detection of AF- I don’t see any difference 
between Bardy and the other systems.’(HCP008). 
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‘I found that 10%, 3 of the 30 recordings - they were meant to be for 7 days 
- and what happened to these recordings is that because the monitor is a 
plaster, when the plaster becomes loose, that generates artificial noise. The 
data then becomes impossible to do any analysis on. That could be a down 
point as well. It could be that it wasn’t fitted properly, or the patient 
removed it, we don’t know. But that could be an issue.’ (HCP008). 
Issues in some poor-quality recordings was noted by the cardiac physiologist who was 
involved in NHS secondary reporting included (periods of QRS under-sensing leading to 
inaccurate R-R plot (n=1); frequent noise from artefact (n=2, with one of these noted to only 
provide 50% of readable data); poor quality recordings (n=3). There is no clear reason why 
there was poor quality from these devices. However, potential reasons of poor-quality ECG 
or artefact may include poor adherence to the skin, this may be due to poor skin preparation, 
hair regrowth, perspiration, impact from water or loss of device adhesive, interference from 
having a mobile phone in close proximity, walking and moving around, wearing a bag and 
wearing an underwire bra. The cardiac physiologist was not concerned however about a 
company actually storing the patient data as long as the security measures are in place. 
‘The data is fine since they have all the security in place.’ (HCP008). 
8.3.2 Report Generation and Analysis 
Due to the national shortage of cardiac physiologists, the main analysis of the reports (n=64) 
was outsourced to the company supplying the device. This involved a cardiac physiologist and 
a cardiac consultant from within the company tagging the data-stream once uploaded from 
the devices and generating a report for clinicians to read (see Figure 8.1).  
Bardy provides an online platform for analysing the ECG data. This platform can be used on 
any computer that has a connection to the internet. The platform provides the tools needed 
for analysing the data and compiling the reports. Using the Bardy platform it currently takes 
a cardiac physiologist roughly double the time to access and analyse all the required data 
points to generate a report compared to the existing systems used for reporting (within NHS 
Lothian). This was reported as being because of (i) the longer loading times for the data and 
(ii) not being familiar with the software. 
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 ‘If I had to choose from what I have now or this Bardy platform, I would 
choose the one that I have now. Because I can do the analysis of 7 days 
monitoring, (…) in about 10-15 minutes and I take double the time in the 
Bardy platform. And the reason for that it takes 1 minute some time to load 
ECG if you want to see a specific point and if you would like to see a few ones 
that takes you a few more minutes, while in the system that I have you just 
click and it takes you there, takes 1 second. (…) if they (Bardy) improve their 
system make it quicker, it would be more or less the same.’ (HCP008). 
Using the current Bardy online platform the clinician has to extract the data (from the device) 
and put the data into another platform in order to generate the report. In other similar 
platforms everything is done on the same system. However, this was not considered to be a 
major problem. 
‘In other systems the reporting and the analysis are in the same platform, 
so you don’t go away. So in this one, you need to go on another platform 
that generates a window but we can still see the other (analysis) platform 
and then we just type everything (…) so it’s something you can do (reporting) 
but it is a bit weird, but it works out -  we can do the report, it doesn’t take 
a huge effort to do the report’ (HCP008). 
Despite the problems with loading time, the online platform for BARDY CAM™ was considered 
easy to use and required little training to get used to using it. 
‘Because it is a new platform, ……I need to know where the buttons are but 
I found that that was kind of easy to start with, it is not something very 
complex that we need a lot of training in. Possibly because I have already a 
few good years of doing analysis in other systems and that allowed me 
possibly to learn the system quicker.’ (HCP008). 
It was noted that issues related to the bespoke software needed to read the data. This led to 
some perceived waste of resources, as some technology had to be returned to the company 
early in the test of change. This issue because of NHS systems not necessarily being ready to 
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work with outside software and so during procurement and initial set up it is important to 
ensure that all software compatibility and governance issues have been addressed. 
 
‘And there was quite a lot of time spent as well around IT issues and how those [health 
care professionals] that were training were going to upload and then interpret the 
data…’ PF001.  
‘We couldn’t put our software- we can’t our hardware onto our network that hasn’t 
been purchased by the NHS.’ PF001 
After training and receiving relevant usernames and passwords, the stroke liaison team 
uploaded the device data to the online server to be analysed. Staff considered this process to 
be a simple one:  
 
‘It’s so simple, you register the patient details and then uploading, it’s just putting it in 
the wee machine and it uploads everything in minutes, seconds, it’s fantastic.’ 
(HCP003) 
 
A selection of these reports (N=28) were subject to a separate secondary analysis conducted 
by an NHS cardiac physiologist at another hospital in Scotland. This was deemed as a 
necessary step in order to (i) evaluate the trust and confidence that the clinicians had in the 
medical device company providing the reports and (ii) to conduct a cost and time comparison 
for a model where the reporting would be conducted within the NHS in the future. Reports 
completed by the company can take up to 2 working days. An example of the reports from 
the company can be seen in Figure 8.1. Reports completed by the NHS cardiac physiologist 
took an average of 45 mins per report once received.  
Major concerns related to the quality of the reporting conducted by the company’s systems 
(for 3 patients) occurred at an early stage of analysis (for example not identifying AF, episodes 
of Ventricular Tachycardia) from the first ten reports. Concerns were raised immediately to 
the company when the stroke consultant received the device reports (these devices were not 
dual analysed at this point). An internal investigation was conducted immediately by the 
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company and the erroneous reports were due to 1. internal processes (which have since been 
changed) and 2. human error. The results of both device reports were reviewed by the stroke 
consultant. When setting up the system within the UK for this implementation, a fault 
occurred meaning that instead of receiving checks by 2 more junior and supervised staff 
members, the report was sent to the clinician immediately after the analysis by the first staff 
member. This issue led to some discrepancies in some initial reports. Discrepancies in early 
reports were highlighted to the company and consequently the quality of the reports 
improved, and no further reporting accuracy issues were reported. The company have now 
resolved this issue but this did highlight the importance of a quick feedback loop between the 
clinicians and the device company to quickly identify and resolve any issues that might have 
an impact on clinical practice. This may have contributed to clinicians expressing preferences 
earlier in the project for inhouse NHS analysis. However, clinicians reported that the company 
were very responsive to feedback in relation to acknowledging this issue and fixing the issues 
in a brief time period.   
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Figure 8.1. Report Produced by the Bardy Platform 
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8.3.3 Trust in the reports  
The participant considered the role of the clinical expertise crucial for the robustness of the 
results. There was a lack of trust in a report generation process that was happening outside 
of the NHS where the process for this reporting and the qualifications of the staff generating 
these reports was unknown. Some of the comments actually referred to not knowing what 
level of machine analysis Vs human analysis was happening and this is something that needs 
to be considered carefully. 
‘You can trust the person that is doing the analysis. (…) Somethings the 
system misses and this is understandable, they miss things because they are 
very complex and technical to explain, but all the systems do their own 
mistakes, that’s why we have a trained specialist to do the analysis and 
identify them and do the reports. (…) We need always to see all the data, 
we cannot trust a computer to do it for us. (…) The system itself needs to 
have some sort of feature that shows us, it flags them to us (…) showing us 
where he thinks it could be something wrong. If the computer does that 
automatically its fine, but we always need to check.’ (HCP008). 
Prior to reviewing the BARDY CAM™ device and creating device reports, the NHS cardiac 
physiologist also reflected on participation in a previous research study in which upon 
reflection he noted the qualifications, experience and ongoing competency of the analysis 
team (within any outsourced company) may be something that requires consideration in 
relation to the trust that is then placed in these reports.  
 
‘So basically you wear the patch and they do everything and then we just receive the 
reports, so I was a bit opposed to that because we don’t know who is actually looking 
at that data if they are capable of, they are trained for.’ (HCP008). 
 
Following participation in this implementation process, the cardiac physiologist involved 
suggested the way the NHS has structured the cardiology teams is very credible and 
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controlled. Any outsourcing to a company does not guarantee that the results would be 
reliable. 
‘For the good sake of our patients we cannot trust a company to do the 
reports and the analysis. I am a specialist and sometimes I do have doubts 
and I ask other consultants and they still have doubts, ‘cause sometimes it 
is very hard to see what it happening in there... I don’t like the idea someone 
doing the analysis and sending us back the report. How can we trust them? 
Who are they? I don’t think that would be a good thing to do.’ (HCP008). 
Another thing that required some design consideration for the outsourced reporting to be 
accepted by the clinicians is the American-English currently used by the Bardy reports. There 
are different terminologies for cardiology related topics in an American and British-English 
context. 
‘Another thing is that this is an American company and something that I 
saw, yes we both speak English, but they have different terminology for 
cardiology e.g. we call “Supraventricular topics” they call it “premature 
atrial contractions” for the same thing. All the analysis I am making is in 
American English. They have to do an UK version of that.’(HCP008). 
8.4 Perceived Costs and Benefits (Value) 
Although the perceived value (to both the patient and the stroke service) from the HCPs was 
overall positive, the financial and time costs associated with this project were noted by the 
HCPs throughout.  
The stroke liaison nurses noted that the large quantity of participants who were included in a 
short period of time for a test of change caused additional work (for the nurses) during the 
test of change but also noted that this could be avoided in further roll out of the service: 
‘We could just have staggered them [the issuing of devices to patients], but that’s just 
not the nature of how we do our work’ (PF001). 
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There were also additional time costs associated with the actual process of managing the 
patient home visits to apply the devices. A stroke liaison nurse expressed: 
‘This took about a day and a half to two days of your week, easily.  In terms of 
organising visits, retrieving things that had gone missing, uploading the devices when 
they came back, chasing the devices from patients that had perhaps not sent them 
back.’ (PF001). 
The stroke consultant also noted that due to anonymity with sending the data from the 
devices without the patients’ number: 
‘This led to masses of my time... looking at the reports and the system ... But actually, 
in the real world the consultant would take pretty much exactly what it currently takes 
to read, 2-3 minutes.’ (PM1) 
In order to ensure recruitment rates within the time frame anticipated, the leading clinician 
commenced identifying individuals who may be suitable to take part in this new pathway, 
who were awaiting AF screening within the current pathway. It was anticipated that the 
project would commence late March 2019, as this period was anticipated, the manager of 
this site had planned accordingly, ensuring adequate staff and planning for a quieter workload 
period. However, due to delays the start date was later than planned, meaning staff were on 
annual leave and it was the busiest period of the year. It also meant that the stroke liaison 
nurses received a list of sixty possible individuals who could be readily recruited into this 
pathway when the project commenced. This significant increase in workload was a negative 
aspect and appeared to be reflected in the analysis of the interviews. This is reflected in the 
below quote.  
 
‘I love it, I really, really do think it’s an excellent service. There has to be a better way 
though of us putting it on, because we had 20 we had to put one in a week and if you 
can imagine we cover the whole of [this area]. So the geography of where people were 
living, we were having to travel to put that on them and do visits as well as. It was 
really, really very, very time consuming and our workload was horrendous. I think we 
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had arranged to do it previously maybe in March time when it was full capacity of staff 
and there wasn’t anybody on holiday. So I think the workload had increased quite 
significantly, but hopefully that wouldn't be every week. So there needs to be an easier 
way of us to work it and I know the guidelines say that it’s for two weeks however we 
get 72 hour holders just now so it would be good if it was just a week, a week long 
patch would be ideal and it would be less time consuming and easier to organise.’ 
(HCP001) 
‘More recently we had a whole batch to do, so that was quite, it was full on really 
trying to get them all done and then getting back a week later along with putting new 
ones on. So that was taking an awful lot of our time because obviously our role goes 
on everyday as normal. So that was like a huge extra that we’re putting in to get that 
done. But if it gets rolled out properly it won’t be the same intensity, so therefore I 
don’t see why it shouldn’t fit in ok with us.’ (HCP006). 
It should be noted however that many of these are a result of this being a pilot and many of 
these issues could be addressed if adopted into mainstream practice. Although these were 
challenges noted, Stroke Liaison nurses noted ways of overcoming these challenges. 
‘But the reality is that if you were using nursing efficiently it would go onto the patient 
before they left hospital and then they would post it back.  Or it would go on the patient 
in clinic and then it would be posted back.’  (PF001). 
The stroke liaison nurses valued the positive impact on the patient but also note the potential 
financial and time savings for various departments within the service.  
‘I think the big savings in the pathway are to the whole system, to the hospital system 
rather than to our part of the pathway.  So the savings are around patient transport 
to attend cardiology.  The cardiology department, time, the use of the Holter.  The 
Holter from the hospital side, so it’s all cardiology time savings, ambulance time, the 
patient’s time and convenience to family members.’ (PF001) 
The positive attitude of the staff and their willingness to put the patient as their priority 
regardless of their workload appeared to reflect a positive working environment, with staff 
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appearing happy to be involved. The positive attitude within this site, appeared to overcome 
the barriers. All HCP interviewed in this project appeared to find benefit in this project 
especially in relation to the patients impact on this care pathway.  
 
‘I was involved in the background, getting a good understanding of the purpose of it, 
the benefit that it is to a client group, especially in relation to stroke care and stroke 
management. The quicker we can identify AF has been an element that could have 
increased that individual person’s risk of stroke, so the early diagnosis means more 
effective and quicker establishing in their appropriate management. So I think the 
early diagnosis and commencing prompt treatment is that the key factors about the 
device.’ (HCP004). 
 
‘I was just delighted that we were given the opportunity to participate because 
obviously I’m acutely aware of the fact that we need to be monitoring people for a 
longer period of time and the impact that has on services and the capacity to do it. So 
anything that was going to expedite that in any way I thought would be really useful 
and that’s why I was keen to bring this to Lanarkshire. ‘(HCP002). 
 
Cardiac physiologists commented on the potential costs and benefits of using such a new 
device compared with the existing technology: 
‘…. it is also much more expensive than the one we have and use at the 
moment. (…) It doesn’t matter to us which system we use to record, since it 
records and it’s a good quality that we can analyse, doesn’t matter if it’s a 
patch or a wee monitor with 2 cables. If we get the data and we analyse the 
data for us it’s the same.’ (HCP008). 
 
The Stroke manager of this NHS site appeared to appreciate the value of the implementation 
of the project from the outset and this appeared to flow down to the staff involved in the 
project to increase professional readiness and buy in early on. 
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8.5 Training and Technical Support 
One thing that the cardiac physiologist commented on was that the company provided the 
monitor and the platform was based in the USA. This created some issues specifically due to 
difficulties in communication. The participant explained that the time difference made it hard 
to contact the company, during working hours, in order to resolve technical issues. However, 
the support when received was very helpful. 
‘Because their IT is based in America, this made things a bit difficult. (…) I 
had to phone at 6pm which is 9am in America to get an IT from the company 
so that’s something that is not ideal. But apart from that, the support was 
good, the training was good, and they were quite helpful on what they could 
do in terms of if there was any issue.’ (HCP008). 
With any adapted pathway (new devices and/or new processes) there are training 
implications. This includes training the health professionals (e.g. device application, reading 
reports) and also training patients on anything related to the device such as charging devices, 
showering, how to wear, how to fill in patient diaries etc.  
 
‘So, there was four, there was three days of training for cardiologists and stroke nurses 
together. And then there was two days of training for stroke nurses and that was all 
with company number one’ (PF002). 
 
During this test of change it was noted by professionals that the company provided excellent 
training but that this was done first with one company and then by another company when 
there was a change in the device distributor in the UK. 
 
‘There was ‘a lag of a year before we actually started, before we were anywhere near 
applying a Bardy.  So, the nurses were then retrained by company number two.’ 
(PF001). 
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Although the training was found to be beneficial it was found to be time consuming for the 
stroke liaison nurses as they were still required to complete their usual workload.  
 
‘[Attending training led to] pulling seven stroke nurses out of clinical time for half a 
day, which is significant in the wards… So, it’s potentially 18 home visits that aren’t 
being done.’ (PF001). 
‘As soon Doc Medical came onboard everything just happened, because they were 
extremely well supported.’ (PF001). 
‘Only half an hour, it didn’t take too long.  Just downloaded it and then plugged in the 
wee uploader and we could all log on, on our computers.  Only that wouldn’t happen 
in my computers, so but the rest of them could, go on their systems… But again, Dot 
Medical talked every person through exactly what they needed to do and then phoned 
them to check that everything was okay, and that they had managed their emails and 
everything.’ (PF001). 
8.6 Role of Innovation Centres in Innovation within the NHS 
 
Although healthcare professionals were aware of the importance of screening for AF in those 
who have had a stroke, some barriers and facilitators may still exist which may prevent or 
reduce the effectiveness of the actual realisation or implementation of new technology within 
the NHS. The role of the facilitators of this process is to work ‘with all of those agencies and 
making sure that communication goes between and trying to bring that collaboration 
together’ (IP003). This role has been seen as a positive within this implementation especially 
at early stages.  
‘so I think it’s been incredibly important and it’s a really interesting process and it’s 
been fascinating to be involved in understanding the real complexity of generating 
change within an organisation and getting buy-in from all the different stakeholders 
trying to ensure we’re doing something that can go forward because instead of seeing 
a study end you hope to be able to have impact and make that work go forward across 
the nation or even further.’ (IP001) 
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At later stages of the project, HCP involved in this implementation process suggested that to 
facilitate the project, key recommendations include having a local collaborator as the main 
form of contact would be beneficial.  
 
‘… it’s not how I’ve worked with other parties whenever we’ve tried any kind of 
implementation. So for example going straight to people in IT in Lanarkshire, going 
straight to senior managers who actually aren’t involved in the process, they may well 
say the right or wrong thing to the […] individual, these things should always be done 
through the person who’s the link in that health board. Apart from anything else they 
understand what’s happening, but they also understand the people who are involved 
and how to approach them and how to ensure we’re getting a speedy resolution to 
issues that arise. So I think that there should be lessons learned from that and there 
should be a local collaborator highlighted and that’s who all of the requests for that 
health board should go through.’ (HCP002) 
 
Other key recommendations include having support and involvement in the initial set up from 
the local R&D department, having a realistic start date with adequate staff numbers and 
workload would ensure the facilitation of future work.  
 
‘I was running about pretty much putting on six or seven in the one day and it was a 
bit ridiculous but I dare say we could cope better if it was maybe two, three, four a 
week. I think it’s doable.’ (HCP001). 
 
‘I think the main barriers were the same as the facilitators, had we had a clearer plan 
from the outset I think things would have been done in a much more streamlined way 
and those have been the main barriers for me is that we’ve waited until we absolutely 
need something to initiate it rather than having it prepared.’ (HCP002). 
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9 Conclusions: Recommendations for Wider Adoption and Scale 
 
This report focused on a process evaluation of AF screening in NHS Lanarkshire. We 
examined patient experience (patients mostly found the device comfortable and acceptable 
and saw value in being able to wear the device and be monitored for 14 days continuously 
at home). We also closely followed clinical and service delivery experiences and reported 
that both senior stroke clinicians and stroke nurses involved in applying the devices highly 
valued the 14 days of continuous monitoring in this patient group. We revealed some 
remaining improvements are needed such as (i) making available a device that enables 14 
days monitoring (battery life) without a switch over to a second device for the second 7 
days, (ii) considering training needs and costs provided both by the commercial provider 
and also by NHS stroke teams and/or cardiac physiologists, (iii) tailoring the reports to the 
local context and (iv) creating transparent demonstrators of how the data is generated from 
the device and used in the reporting system (currently manually tagged by experts in the 
commercial company) to increase trust in the reporting process in order to realise full 
benefits of contracting full service to the commercial provider and (v) further considering 
the costs and workforce implications in NHS boards choose to generate the reports in house 
in the NHS. 
 
9.1 Strengths and Limitations of this project 
This evaluation was innovative in that it was embedded within the entire Test of Change 
process from procurement through to implementation and evidence generation. This 
involved a collaborative partnership between one NHS board, academic partners, a 
commercial provider and an innovation centre. This meant implementation and evaluation 
were embedded throughout the project and generated evidence to support adoption of this 
new service within the local context. Wider adoption was also considered throughout the 
process evaluation and real-life experiences were captured, thereby providing usable 
insights for others to inform their adoption of this service (or services like it) within different 
clinical sites and contexts. 
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However, one limitation that was observed was the lack of a defined dedicated 
implementation or process project manager from the project outset. There were defined 
clinical leads, technical leads, commercial leads and evaluation leads but no one designated 
party specifically responsible for implementation management overall. Consequently, 
unexpected set up delays were encountered initially, impacting on activities associated to 
establishing roles and responsibilities and producing appropriate data sharing agreements. 
It also meant that recruitment and data collection responsibilities were ultimately shared, 
taking time to negotiate especially within the NHS context where it is still often unclear 
whether these types of evaluation require NHS ethical approval (as research) or not (as 
service evaluation). To ensure tasks were completed, the health care professionals and 
academic team took a larger role in the implementation and project set up than originally 
anticipated. It could be argued that this resulted in the evaluation team becoming less 
objective than initially planned and this may have impacted the perspective of the project. 
However, the resulting benefit of this is an evaluation that is much more action research 
based and that allowed us to capture wider planning and implementation barriers and 
facilitators across time from various stakeholders throughout the project. An additional 
benefit is that the innovation centre has now put in place a process to ensure that 
partnership projects are fully resourced either by itself or one of the partner organisations 
and that this is formalised through revised project documentation to maximise working 
arrangements across the partnership.   
Although this approach did not allow us to systematically compare delivery of the new 
service to the existing one, it did allow for an innovative new service model to be tested 
with real patients in order to monitor how acceptable they found the new service. Of note, 
our approach also allowed us to capture the perceived value of the new technology enabled 
service to the patient (including staying at home, less hospital visits, less travel, receiving 
treatment more quickly, for example). We encountered some recruitment challenges, with 
a smaller number of patients recruited than originally planned (n=8 instead of n=20). This 
may have been partly due to the process of patient referral and due to a limited time for 
recruitment caused by delays in the project implementation itself. This may decrease the 
generalisability of the study results in relation to overall patient experience.  
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One major advantage of this study was that healthcare professionals were interviewed at 
various points during implementation which allowed us to capture a wide range of barriers 
and facilitators to the service implementation. Future service evaluation research should 
continue to place a strong emphasis on gathering evidence around patient experience, 
clinical experience, and the factors that increase readiness to implement alongside any 
other ongoing clinical feasibility and/or cost benefit economic studies. 
This process evaluation allowed us to gain insight into how the implemented device and 
managed service was implemented in one particular context. These findings can now be 
used for this board to consider whether to adopt this device and service into routine 
practice or to consider alternative devices and associated digitally enabled services. In 
relation to the device itself, one specific limitation to note is the device deployed in this test 
for change was designed to have a battery lasting for 7 days. This means the true experience 
of collecting 14 days continuous data was not fully realised but this was unavoidable as a 
device with 14 days batter for continuous monitoring did not exist at the time of 
procurement. It did however allow clinicians and stroke nurses to gain invaluable insight 
into how they would make this work in practice. As the devices improve, and the reporting 
process is refined, it is advised that decisions are made now with regards to whether the 
reporting is done inhouse (within the NHS) or whether it is outsourced to a device company. 
If the latter approach is adopted, then the reporting would need to be tailored to the local 
needs and context and specific targeted information strategies focusing on increasing 
clinicians trust in new devices and third party reporting (and machine learning if this 
becomes part of the system) need to continue. 
9.2 Recommendations 
Figure 9.1 shows a key set of interrelated implementation activities that are key to the 
successful adoption and scaling of new technology enabled care services. Furthermore, in 
order to provide generalisable and usable results from this test of change a 
recommendations checklist has been developed (see Table 9.1) so that the findings of this 
service evaluation can be readily applied to other real-life implementation studies. Some 
examples from this project are provided in the table but the checklist can also be used for 
different contexts and different sites (for example with different technologies or different 
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service models or populations and contexts). It is advised that in addition to these key 
recommendations, researchers should also continue to draw upon recent appropriate and 
validated theoretical frameworks in the development of their projects (for example, the 
NASSS framework (Greenhaugh et al, 2017). 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 Figure of 8, showing the eight aspects of implementation to be considered 
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P-domain Description 
Purpose 
 
The reasons for implementing the new technology enabled service. These could be to 
save time, reduce costs, improve patient experience, change the way or working, 
reduce waiting times for example. 
Population 
 
The intended target population (patient, service user, citizen).  There may already be 
existing evidence for this technology being used in this population.  It might be 
important to consider how the service might extend to other populations.  
Planning and 
Preparation  
 
The preparation that is required (both pre-implementation and during and after the 
implementation process). Technical infrastructure, workforce readiness, resource 
allocation, and issues around data collection/monitoring and governance all need to 
be considered. 
Procurement 
 
The process of procurement in health innovation is ever changing and has to adapt to 
keep pace with the advances in technologies (e.g. smaller companies producing 
devices and managed services). Embedding evaluation and implementation 
champions or leads in the procurement process should lead to better evidence being 
generated and possibly accelerated routes to market for smaller companies. 
Pilot 
 
Even during implementation, the role of pilots should be considered. These could be 
short agile user testing in context type pilots either pre-procurement (to inform 
procurement) or after procurement but pre roll out to minimise risks that the 
technology or service is not fit for purpose. 
Patient 
Experience 
 
To optimise patient or user adoption and acceptance, experience of the patient/user 
needs to be considered. Implementations programmes should consider how best to 
capture this even beyond evaluation and embedding this in the service itself. 
Process 
(implementation 
and evaluation) 
 
Process evaluations should continue to be conducted alongside clinical trials in order 
to maximise chances of adoption and scale. The feasibility and workability of a 
technology enabled service is likely to increasingly depend on smoothing the process 
of implementation alongside clinical efficacy. 
Practice and 
Policy  
 
It is critical to consider if and how practice and policy are either informing or 
influencing the design of the new service and how the results of any new 
implementations might inform future practice and policy. 
 
Table 9.1. Table provides a description of the main P domains for the implementation process. 
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 Recommendations for the Implementation of Technology Enabled Services 
 Recommendation 
 
 
Checklist Question for Implementers* 
 
*Implementers could be health professionals, commercial 
device or service providers, evaluators, decision makers. 
 
Has this been 
completed 
satisfactorily? 
Indicate Yes/No 
1 Purpose, population and Preparation 
 
  
1.1 Identify the primary intended purpose of the 
service/intervention and clarify this with all partners. 
Have you identified and clearly stated the primary intended 
purpose of the service/intervention and gained sign off on this 
with all partners? 
 
1.2 Identify what population is being targeted as this might 
affect (i) what is implemented and (ii) what the 
implementation and evaluation priorities are. 
Have you confirmed the population that is being targeted for 
the implementation/intervention/service? 
 
1.3 Conduct a preliminary stakeholder analysis and identify 
and prioritise the intended primary desired outcome of 
each stakeholder 
Have stakeholders been identified, consulted about their 
requirements, and involved in the evaluation design and 
implementation? 
 
1.4 Identify and agree scope of implementation and 
evaluation and align with business case requirements at 
earliest opportunity.  
Has the scope of the evaluation and its alignment within the 
business case (evidence needed) been identified and agreed? 
 
1.5 Conduct a requirements analysis and identify and 
prioritise business needs, clinical needs, technical needs, 
service delivery needs, and patient acceptance/end user 
needs. 
Have you conducted a requirements analysis and identified and 
prioritised business needs, clinical needs, technical needs, 
service delivery needs, and patient acceptance/end user 
needs? 
 
1.6 Create a data management plan and agree this with NHS 
and commercial partners prior to Go Live date. 
Has a data management plan been agreed with NHS and 
commercial partners before the Go Live date? 
 
1.7 Create and use Data Sharing Agreements at procurement 
and pre-planning stages. 
 
Has a Data Sharing agreement been created at early stages 
prior to procurement? 
Have GDPR risk assessments been completed at early stages? 
 
1.8 Consider whether the project is considered an NHS 
research project (requiring NHS ethics review) or service 
evaluation. 
 
Have all partners agreed the project is considered a research 
project or service evaluation? 
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2 Procurement and Pilot  
 
  
2.1 Form an innovation partnership with the NHS board, 
service provider, and evaluation partners from the outset. 
 
Has an innovation partnership been formed with the NHS board 
and evaluation partners? 
 
2.2 If possible/required, pilot the project using a smaller 
number of patients/users. 
 
Will the device/service be piloted on a small number of users 
prior to procurement or implementation? 
Has the device/service been piloted here or elsewhere? 
 
 
3 Planning and Process   
3.1 Identify service design, delivery, implementation, and 
evaluation leads and create a working group to identify 
roles and responsibilities. 
 
Have service design, delivery, implementation and evaluation 
leads been identified?  
Has a working group been created? 
Have roles and responsibilities been outlined? 
 
 
3.2 Identify (and or plan to gather) evidence for patient 
acceptance as well as efficacy/accuracy/reliability. 
Is there existing evidence for / are you collecting data that will 
help you generate evidence for patient acceptance? 
 
 
3.3 Provide project managers with change management and 
implementation experience. 
 
Do the project managers have change management or 
implementation experience? Or is further training or support 
needed? 
 
3.4 Embed evaluation and implementation throughout. 
 
Has the evaluation and implementation been embedded 
throughout? 
 
3.5 Develop a specific implementation strategy and plan per 
site – create a template for planning based on NASSS as 
an appendix or point people to complete the planning 
document by Greenhalgh et al? 
Has an implementation strategy/plan been based upon a 
framework such as NASSS? 
 
3.6 Consider wider technical infrastructure and systems 
requirements early in procurement and delivery process. 
Have wider technical infrastructure and system requirements 
been considered early in procurement and at delivery stages? 
 
 
3.7 Provide access to tech support throughout project – rapid 
resolution to any challenges encountered is key to keep 
momentum and adoption pathway. 
 
Will technology support be available throughout the project? 
Is support available within the same time zone where the 
technology is being used? 
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4 Practice and Policy 
 
  
4.1 Have a clear communication plan for clinicians / health 
professionals “on the ground” with expected / anticipated 
dates of delivery, rollout, unexpected delays etc. 
 
Has a clear communication plan been created (with 
expected/anticipated dates of delivery, rollout delays etc)? 
 
4.2 Set realistic goals and track them – i.e. deploy to X sites in 
one go then gradually increase, or deploy to X patients 
then gradually increase etc. 
Have realistic goals been set? 
Will they be tracked? 
 
4.3 Provide appropriate training at timely point pre-
deployment if considered too long, from the initial 
training, this  should be repeated. 
Has appropriate training been arranged prior to deployment?  
4.4 Identify possible barriers at each site / locality pre-
deployment and any existing barriers. Consider how local-
level barriers could be translated to facilitators with 
appropriate activities / support. 
Will/ have possible barriers been identified at local sites pre- 
deployment? 
How will facilitators overcome these barriers? 
 
 
4.5 Work with hospital communications / marketing team to 
raise awareness of the change in service from the inside 
and externally so people know things are changing, why 
they are changing and when they are changing. 
Will the hospital communication/marketing team be 
contacted? 
 
 
4.6 Have key champion(s) at the deployment site to encourage 
others along the implementation pathway.  
Have key champions been identified at the deployment site to 
encourage others along the implementation process? 
 
4.7 Involve R&D early and form a partnership between them 
and the implementation and evaluation teams. 
 
Has a partnership been formed between the implementation 
and evaluation team? 
Will R&D been involved at early stages? 
 
4.8 Involve local IT and form a partnership between them, the 
tech service provider, and the implementation and 
evaluation teams. 
Has a partnership been formed with local IT, tech service 
provider(s), implementation and evaluation teams? 
 
4.9 Conduct workforce planning prior to implementation (to 
identify roles, shifting roles and training needs) 
Has workforce planning been conducted (to identify roles, 
shifting roles and training needs)? 
 
4.10 Create time and budget for initial and ongoing training 
costs 
Has a time and budget been set for initial and ongoing training 
costs? 
 
4.11 Identify what is needed for the business case both locally 
and in the wider scale up environment. 
 
Have the requirements for the business case been outlined 
(both locally and in the wider scale up environment)? 
Can these requirements be linked to National strategies? 
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4.12 Identify audience for outputs of the implementation. Has the audience been identified for the output of the 
implementation? 
 
4.13 Some implementation could be mandated by the 
Government to provide a higher-level structure of support 
for the change. 
Should implementation be mandated by the Government to 
provide a higher-level structure of support for the change? 
 
4.14 Prioritise outcomes (clinical, cost-benefit, patient 
acceptance, clinical acceptance, feasibility, scalability). 
Have the outcomes (clinical, cost-benefit, patient acceptance, 
clinical acceptance, feasibility, scalability) been prioritised? 
 
4.15 Awareness of context and identification of parts of the 
deployment process or activities that can be adapted to 
local context to best work within existing structures.  
Have parts of the deployment process/activities been adapted 
to the local context to work within the existing structures? 
 
 
4.16 Monitor and evaluate implementation progress and adopt 
corrective actions where necessary. 
 
Will implementation progress be monitored and evaluated? 
Will corrective actions be adopted where necessary? 
 
4.17 Work alongside HCP team to allow some tailoring of 
implementation to specific contexts – i.e. is it feasible for 
nursing staff to travel to every patient’s house to do the 
switch over or collect devices? How can this process be 
better streamlined to still be time efficient for patients and 
staff? Important for remote and rural deployments. 
Can the process of implementation be amended to be more 
efficient depending on the site? 
 
4.18 Share successes – e.g. first patient recruited / device 
deployed etc 
Will successes be recorded? 
How will they be recorded? 
Where and how will they be shared? 
 
 
 
Table 9.2. Table outlining recommendations and checklist for implementation.  
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If the answer was no to any of the above items; please describe details:  
Person(s) completing form, please sign and date: 
 
______________________________________________ 
 
______________________________________________ 
If the answer was yes to any of the above items and you wish to record more detail, please do so here:  
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Appendices  
 
Appendix 1: DHI Market Review 
 
The below has been used with permission. Reference: Digital Health and Care Institute 
(2018). Ambulatory electrocardiography equipment: A market analysis of wearable 
technologies measuring heart output. 
Ambulatory electrocardiography equipment: A market analysis of wearable technologies 
measuring heart output 
The aim of this document is to provide a brief overview of “Conformité Européene” (CE) 
marked continuous monitoring technology used in measuring cardiac output for the purposes 
of detecting Atrial Fibrillation (AF), specifically for patients following the onset of a stroke  
In Scotland the standard and most the most cost-effective method for detecting AF is through 
opportunistic screening of 65+ year old patients by radial pulse checking followed as soon as 
practicable by a 12-lead electrocardiogram for those with an irregular pulse. 
The most well-known AF monitoring technology, with built in algorithms that interpret the 
recorded data is AliveCor’s heart monitor and associated AliveECG app. The AliveCor Heart 
Monitor and AliveECG app were CE-marked to AliveCor as a Class IIa medical device in January 
2015. What follows are a selection of alternative ECG monitors on the market. 
Zio Service iRhythm 
The Zio service received it’s CE mark as a Class IIa device in December 2014, for its continuous 
heart monitoring. The technology is a remote cardiac monitoring system used to detect 
cardiac arrhythmias. The service is comprised of the Zio patch, an adhesive patch containing 
a 1-lead electrocardiogram, and the Zio report, am analysed summary of the recorded data. 
The patch is placed on the patients left upper chest and can record up to 14 days of 
continuous heart monitoring data, patients are also asked to record a written log to record 
any symptomatic events that happen during the monitoring period. Following the monitoring 
period, the patient removes the oatch and posts it (via royal mail). The recordings are 
analysed by the company, using proprietary machine-learned algorithms, Zio ECG Utilisation 
Service System (ZEUS System), and a report is produced. Said report contains all cardiac 
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arrhythmia events over the monitoring period and is analysed by a trained cardiac technician. 
The report is sent electronically to the patient’s clinician via iRhythm’s web-based portal. The 
full ECG is available upon request from the clinician. Parts of the analysis occur in the UK and 
the USA, with all transmissions, data storage and analysis complying with all relevant EU and 
UK legislation.  
Cost 
The price of the Zio Service currently stands at £800 per unit (excluding VAT). This price 
includes the patch, the data analysis and the report for one individual patient. In practice, the 
price will vary depending on the procurement and volume arrangements of individual 
healthcare institutions. The resource impact would be increased monitoring costs compared 
with 24-hour Holter monitoring, but this could be offset if Zio Patch were shown to increase 
early and correct diagnoses and reduce repeat monitoring and admissions.  
Cardiologic Bardy Carnation Patch, the Carnation Ambulatory Monitor (CAM) 
The CAM is a P-wave centric ECG monitor, the CAM is a single patient use monitor that records 
a continuous ECG for up to 7 days. The CAM is a heart monitor can be worn discretely, in the 
centre of a patient’s chest. The carnations P-wave centric detection is the result of combining 
the sensors placement over the sternum atop the atria. The CAM report is emailed to the 
patient’s clinician, with a focus on any notable events that have occurred over the monitoring 
period.   
Spyder 
The Spyder wireless ECG monitoring system is a wearable ECG sensor that monitors heart 
rhythm via Bluetooth enabled device. The SPYDER is attached with an adhesive pad to the 
patient’s chest and is advertised as being inconspicuous when worn, allowing patients to 
behave normally whilst being monitored. The SPYDER continuously measures and transmits 
real time ECG signals to a computer server that is programmed to identify abnormal patterns. 
Clinicans can review these recordings via secure web based interface, named DoctorSpyder. 
All ECG data is encrypted and only authorised users will have access to ECG data, the ECG data 
can also be analysed and reported in the same manner as a traditional holter ECG. All 
detected anomalies are brought to the attention of the patient’s clinician, allowing them to 
consider the best course of action for the patient. 
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Cost 
The Spyder ECG wireless monitor is sold by SPYDER for $299 for the Spyder personal monitor, 
they also offer a bundled in Spyder personal with an android smart phone (pre-loaded with 
the Spyder App) for $499. 
SEEQ MCT monitor 
The SEEQ Mobile Cardiac Telemetry (MCT) System is comprised of a the MCT wearable sensor, 
the SEEQ transmitter, the Medtronic monitoring centre and the final clinical report. The SEEQ 
sensor is a wire-free device that provides continuous monitoring for a patient over 7.5 days, 
with multiple sensors allowing for up to 3 days of monitoring, the wearable sensor transmits 
data to the SEEQ transmitter via Bluetooth connection, automatic event transmission is 
performed using cellular networks and data is transmitted to the Medtronic monitoring 
centre. The centre provides 24/7 reviews of incoming ECG data and report generation, these 
are analysed by trained cardiographic technicians, the final reports are accessible 24/7 online. 
There are no publicly available costs for the SEEQ MCT Medtronic service. 
 
Other monitors 
The Reveal LINQ became CE marked in February 2014 is an insertable cardiac monitors (ICM) 
produced by Medtronic, the device is around one-third the size of a AAA battery, making it 
more than 80 percent smaller than other ICMs. The device is part of a system that allows 
clinicians to continuously and wirelessly monitor a patient's heart over a three-year period, 
with 20 percent more data memory than its larger predecessor, the Reveal® XT.  Additionally, 
the system provides remote monitoring through the Carelink Network, through this 
healthcare professionals can request notifications to alert them if their patients have had any 
cardiac events. The Reveal LINQ system also includes the new MyCareLink Patient Monitor, a 
simplified remote monitoring system with global cellular technology that transmits patients' 
cardiac device diagnostic data to their clinicians from nearly any location in the world. Reveal 
LINQ costs fluctuate between regions in Europe and further afield, however comparative 
analysis with previous iterations of Medtronic ICM’s have shown Reveal LINQ to be more cost 
effective. The Reveal LINQ approximately £1,500 per device. 
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The Coala is a CE-approved Class IIa medical device system approved for home use. It's based 
on advanced technology that is simple and very easy to use. A wireless and cloud-based 
service that allows anyone, anywhere to quickly check their heart. The Coala is available in 
two versions; Coala sold direct to consumers and the Coala Pro offered to caregivers.  Coala 
enables simultaneous ECG and digital heart sound recordings, with advanced, smart ECG 
algorithms developed in collaboration with the Karolinska Hospital and Lund Universities, 
providing near real time results in the Coala App. The Coala heart monitoring service is 
currently only available in Sweden, but can be easily adapted and licenced for other regions. 
The premium package in Sweden COSTS approximately £121 for the monitor, followed by a 
subscription of £28 per month. 
Mydiagnostick is a CE marked medical device that records high-quality ECG and analyses it 
within 60 seconds. It is a medical grade 2a device, with a patented algorithm so it can signal 
for AF via red or green LED light (the red light means you should contact your clinician). The 
accuracy of MyDiagnostick is over 90% sensitivity and 95% specificity and the MyDiagnostick 
device is priced at €850.00. 
The Omron HCG-801 is a CE marked compact, patient operated, handheld that is designed as 
a single lead electrocardiogram that records 30 seconds of ECG data. The omron Heartscan 
monitor costs £399.99 (exclusive of VAT), this price includes HeartScan ECG Software, and is 
suitable for use in all primary and secondary care environments. It offers the opportunity to 
effectively screen large patient populations reducing referral rates and costs. 
Microlife’s BP A200 AFIB device is a CE marked blood pressure monitor with stroke risk 
detection. The A200 AFIB is equipped with Microlife’s unique AFIB technology, which makes 
it possible to detect atrial fibrillation while measuring blood pressure at home. The package 
consists of the actual monitor and its blood pressure cuff. Microlife AFIB detects AF with high 
accuracy (sensitivity 98%, specificity 92%) as demonstrated in multiple comparative studies 
with ECG, indicating that it can be used as a reliable screening test for early diagnosis. The BP 
A200 AFIB can be purchased for £128.78 (including VAT). Microlife also offer the WatchBP 
another blood pressure device that can detect Atrial Fibrillation with an accuracy upwards of 
97%, and can be purchased for around £108.  Abbott have recently debuted their CE marked 
smartphone compatible ICM Confirm Rx. Its companion app myMerlin serves as an integrated 
transmitter and symptom recorder, as well as a repository of resources for the patient. The 
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app encrypts wireless communications ensuring a secure and protected remote monitoring 
service. The device currently has a 2-year battery life.  There currently is no public pricing 
available. 
QardioCore is a CE marked wearable device that is paired with the Qardio heart health iOS 
application. Priced at £449, the device allows for continuous screening for AF. The device has 
been clinically validated and allows for ECG data to be shared with healthcare professionals. 
Qardio’s QardioArm blood pressure monitor, costing £99, can also monitor for irregular 
heartbeat to provide a warning sign for AF. 
Ongoing Research 
Currently there is a comparison study of continuous sternal ECG patch monitors trial, the 
study compares the carnation patch system with the Zio patch, as these represent the current 
standard for continuous recording of an ECG for extended periods. The study will encompass 
monitoring for AF, syncope, presyncope, palpitations and supraventricular Tachycardia, and 
its primary focus of the study will observe the ECG signal quality, while the secondary focus 
will observe device comfort. The aim of research is to confirm the clinical value of a new P-
wave sensitive recording vector combined with an easy-to-use long-term cardiac rhythm 
monitoring patch system, the CAM System. The P-wave is a critical aspect of the 
electrocardiogram and a key finding for proper arrhythmia diagnosis. The CAM system is 
optimized for both ease of use and for maximum P-wave clarity for arrhythmia diagnosis. 
Note - Since this review was completed in 2017-2018, the study findings have been published. 
Their findings indicate that the rhythm specificity was higher in the CAM system compared to 
the Zio XT patch (Rho et al, 2019).  
Another study performed in 2017 was a ‘randomised clinical trial of early prolonged 
ambulatory cardiac monitoring after stroke; interim analysis’. The study was performed due 
to the fact that paroxysmal atrial fibrillation often goes undetected by the short-duration 
holter monitors. There is a need for a patient-friendly long-duration cardiac monitoring 
system for stroke patients which can be performed without significant delay from the index 
event and with superior yield to Holter ECG’s. the study conducted randomised controlled 
trial of cardiac monitoring after an ischaemic stroke or TIA to increase detection of 
paroxysmal atrial fibrillation using a wearable water-proof adhesive cardiac monitoring patch 
that can be fitted immediately by the clinician early after the index event for up to 14 days or 
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a standard Holter ECG. The interim analysis detected PAF in 4/17 cases in the active arm and 
0/16 cases in the control arm. The commonest arrhythmias detected were atrial 
tachyarrhythmias followed by PAF. Those in the control arm of Holter ECG’s had significant 
delays to initiate cardiac monitoring due to scheduling delays and patient non-attendance. 
There were no device-attributable serious adverse events. The conclusion of the study stated 
that the convenience of the Zio Patch cardiac monitor substantially increased the uptake and 
efficiency of cardiac monitoring early after ischaemic strokes and TIA. 
Below is a list of multiple AF monitors with active licensing as medical devices. These do not 
all fit the specifications of the research request, but this is a clear representation of the 
market.  
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Device Name Manufacturer 
Insertable cardiac monitors 
Reveal LINQ Medtronic Inc. 
Reveal XT Medtronic Inc. 
Reveal PLUS Medtronic Inc. 
External loop recorders 
ER920-AF Series Event Recorder Braemar Manufacturing, LLC 
ER900L-RT Event Recorder Braemar Manufacturing, LLC 
PER 900 Braemar Manufacturing, LLC 
Heart 2006 Dual Channel Loop Event Recorder Aerotel Medical Systems (1998) Ltd. 
Vitaphone 1-Channel ECG Loop Recorder Vitasystems GmBH 
Vitaphone 3-Channel ECG Loop Recorder Vitasystems GmBH 
GemsTrak AF Monitor Universal Medical Inc. 
Heartrak Smart AF Universal Medical Inc. 
Cardioblue Recorder Meditech Ltd. 
CardioCall VS20 Spacelabs Healthcare Ltd. 
CG-6106 Personal 1-Lead ECG Transmitter With Memory LifeWatch Technologies Ltd. 
CG-7100 Personal 12-Lead ECG Transmitter With Memory LifeWatch Technologies Ltd 
Ambulatory Holters 
Chroma RZ153c Holter ScottCare Corporation 
3 Channel Digital Holter Recorder BIOX Instruments Co. Ltd. 
Ambulatory ECG System/Holter Recorder BIOX Instruments Co. Ltd. 
DL900 Series Holter Monitor Braemar Manufacturing, LLC 
Holter ECG Model DL800 Braemar Manufacturing, LLC 
SEER 1000 GE Medical Systems Information Technologies, Inc. 
SEER 12 Holter Recorder GE Medical Systems Information Technologies, Inc. 
SEER Light GE Medical Systems Information Technologies, Inc. 
CardioMem CM 4000 Getemed Medizin-Und Informationstechnik Ag 
CardioMem CM 3000 Getemed Medizin-Und Informationstechnik Ag 
Lifecard CF Recorder Spacelabs Healthcare Ltd. 
Lifecard 12 Recorder Spacelabs Healthcare Ltd. 
Spiderview Holter Sorin Group Italia S.R.L. (Sorin CRM) 
DigiTrak XT Philips Medical Systems 
H12+ Holter Recorder Mortara Instrument Inc. 
H3+ Holter Recorder Mortara Instrument Inc 
CardioMera Recorder Meditech Ltd. 
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QRS Q100/HE Digital Recorder National Biomedical, LLC DBA QRS Diagnostic 
AR12 Plus SCHILLER AG 
AR4 Plus SCHILLER AG 
FD5 Plus SCHILLER AG 
FD12 Plus SCHILLER AG 
MT-101 SCHILLER AG 
External Mobile Cardiac Telemetry 
Telesentry Recorder Model TS01 ScottCare Corporation 
HeartView Aerotel Medical Systems (1998) Ltd. 
AliveCor Mobile ECG AliveCor, Inc. 
Vitaphone Tele-ECG Card Vitasystems GmbH 
HeartCheck Handheld ECG Monitor CardioComm Solutions, Inc. 
HeartCheck ECG PEN Cardiocomm Solutions, Inc. 
Infinity M300 Draeger Medical Systems, Inc. 
Telemetry Transmitter Mortara Instrument Inc. 
ECGBT2 Norav Medical 
SelfCheck 1/12-Lead ECG Event Monitor LifeWatch Technologies Ltd. 
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Appendix 2: Scoping Review SEARCH TERMS 
 
Search Strategy.  
Review: conducted 4th September 2019 
PubMed: ,"Search (((((((((((((((((((((((((((((Ambulatory[Title]) OR ECG[Title]) OR 
Electrocardiography[Title]) OR Ambulatory Electrocardiography[Title]) OR Monitoring[Title]) 
OR Diagnosis[Title]) OR Screening[Title]) OR Heart monitor[Title]) OR Continuous 
monitoring[Title]) OR cardiac telemetry[Title]) OR mobile[Title]) OR cardiac[Title]) OR 
telemetry[Title]) OR EKG[Title]) OR Remote monitoring[Title]) OR Outpatient 
monitoring[Title]) OR Home monitoring[Title]) OR Cardiac monitor[Title]) OR Recorder[Title]) 
OR Patch monitor[Title]) OR Patch device[Title]) OR Single lead[Title]) OR Multi lead[Title]) OR 
monitor[Title]) OR mhealth[Title]) OR m-health[Title]) OR mobile health[Title])) AND 
(((AF[Title]) OR Atrial Fibrillation[Title]) OR atrial fibrillation[Title])) AND ((((Stroke[Title]) OR 
Cerebrovascular Accident[Title]) OR CVA[Title]) OR Cerebrovascular Stroke[Title]) Filters: Full 
text; published in the last 10 years",182,18:11:58
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Appendix 3:  Scoping Review Findings 
 
 Device 
Category 
Reference  Where? When? Sample 
size 
Type of 
Study/Methods 
Devices used? Number 
of 
devices 
used 
AF 
screening? 
CVA 
population? 
Length of time?  Findings Included to 
next stage? 
& Reason.  
Non-
ECG 
monitori
ng &  
ECG 
screenin
g (multi 
lead) 
Pulse 
palpation. 
Fitzmaurice 
et al, 2014. 
United 
Kingdom 
Multi-site 
(n=50). 
2001-
2003. 
N= 425. Randomised 
Controlled Trial. 
Pulse 
palpation & 
ECG. 
1 (ECG). Yes. Yes. Seconds - 
Opportunistic/s
ystematic 
screening.  
N= 149 
episodes 
of AF 
identified.  
No. Not 
continuous 
monitoring 
(-). 
Blood 
pressure 
machine. 
Wiesel et 
al, 2013. 
United 
States of 
America. 
Not 
reported.   
N=139. Study. Microlife BP 
monitor & 
Heartrak 2; 
Mednet 
Healthcare, 
Ewing, New 
Jersey). 
2: BP and 
ECG 
recording
. 
Yes. Yes. Daily recording 
for 30 days.  
2 
individual
s with no 
history of 
AF, had AF 
diagnosed
.  
No. Not 
continuous 
monitoring 
(-).  
Blood 
pressure 
machine. 
Gandolfo et 
al, 2015.  
 
Italy Not 
reported.   
N=207 Observational 
Study 
AFib model 
BP3MQ1-2D 
(Microlife 
USA, 
Dunedin, FL)  
 
2: BP and 
ECG 
recording
.  
Yes Yes 10-minute 
session: 48 
hours after 
stroke.  
N=38 
individual
s 
identified 
with AF. 
Failed to 
diagnose 
n=4 
individual
s. Led to 
false 
identificat
ion of AF 
in n=2 
individual
s.  
No. Not 
continuous 
monitoring 
(-). 
Handhel
d 
technol
ogy & 
Single 
lead 
monitorin
g device & 
Levin et al, 
2014. 
Sweden Not 
Reported
.  
N= 249.  Study.  Zenicor-EKG; 
Zenicor 
Medical 
Systems AB) 
2: 
Handheld 
device 
and 
Yes Yes Intermittent 
monitoring (10 
seconds; twice a 
day) for 30-day 
Total N= 
17 
Yes, 
continuous 
monitoring 
used but 
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ECG 
screenin
g (multi 
lead) 
Holter 
monitor.  
& Holter 
monitor 
(Braemar 
DL700 
analysed by 
Aspect 
3.81R3a; GE 
Health- care, 
Chalfont St. 
Giles). 
 
Holter 
monitor.  
period and 24-
hour Holter 
monitor.  
diagnosed
. 
15 with 
intermitte
nt and 2 
with 
Holter 
monitor.   
noted not 
>72 hours (-
).  
Single 
lead 
monitorin
g device & 
12 lead 
ECG & 
Holter 
monitor  
Engdahl et 
al, 2013. 
Sweden Not 
reported.  
N=848 Study Zenicor 
Medical 
Systems AB  
 
Up to 3 
devices: 
Handheld 
device 
and 12 
lead ECG 
& 
potential 
of Holter 
monitor.  
Yes Yes Daily 20-30 
seconds of ECG 
for 2 weeks. 
10 
diagnosed 
with ECG. 
30 
diagnosed 
with AF 
using 
handheld 
monitor.   
Yes. For 
discussion. 
Ability of 
hold was 
assessed by 
study 
nurse. 
Those who 
had poor 
signal 
offered 
opportunity 
to have 
Holter (+).  
Holter 
monitor 
and 
handheld 
device 
Poulsen et 
al, 2017. 
Denmark 2012-
2015 
N=100 Study  Zenicor-ECG 
(enicor 
Medical 
Systems AB, 
Stockholm, 
Sweden)  
And Holter 
monitor (A 
Lifecard CF 
(Del Mar 
Reynolds 
Medical, 
Irvine, Calif.)  
).  
2 devices: 
Holter 
monitor 
and 
handheld 
device  
Yes Yes 30 seconds 
twice a day: 30 
days (handheld 
device); 5-day 
monitoring 
wearing Holter 
monitor.  
20 
identified 
with AF. 
handheld 
device. 
Only 10 of 
these 
noted 
with both 
methods.   
Patient 
experiences 
relating to 
bother 
noted. 
Ability to 
hold device 
impacted 
quality of 
thumb 
holding 
device.  
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Holter 
Monitor 
and 
handheld 
device.  
Doliwa 
Sobocinski 
et al,. 2012  
Sweden Not 
reported 
N=249 Clinical Trial Braemar 
DL700 
analysed by 
Aspect 
3.81R3a; GE 
Healthcare 
and Zenicor 
EKG®; Zenicor 
Medical 
Systems – 10 
s Rhythm 
Recordings 
once in the 
morning and 
once in the 
evening for 
30 days  
Handheld 
device 
Yes Yes 30 days 
(intermittent) 
AF 
diagnosed 
in n= 17 
patients 
Intermitten
t screening. 
May not be 
suitable for 
all in stroke 
population.  
 
ECG 
screenin
g (single 
lead) 
ECG 
screenin
g (multi 
lead) 
Monitorin
g patch & 
Holter 
monitor.  
Lumikari et 
al. 2019  
Finland Not 
reported.  
N=57 Clinical Trial Bittium Faros 
180° ECG 
 
ECG machine 
not reported.  
2 devices.  
Single 
lead 
monitor 
& ECG.  
Yes Yes Up to 4 weeks. New AF 
detected 
in 12.3% 
(n=7) of 
patients. 
Four of 
which 
were 
asymptom
atic.   
Yes. Note. 
Skin 
irritation 
reported 
(n=2); 2 
devices 
damaged 
due to 
shower.  
ECG 
screenin
g (single 
lead) 
Monitorin
g patch 
Akiyama et 
al, 2017.  
Japan 2016..  N= 1 Case study Duranta  1 device. 
Single 
lead 
monitor.  
Yes Yes 11 days AF noted 
on 5th and 
9th days 
after 
stroke.  
Yes.  
ECG 
screenin
g (multi 
lead) 
Wearable 
devices 
Yayehd et 
al, 2015.  
Italy Not 
reported 
N = 56. Observational 
study. 
Spider Flash 2 channel 
ECG 
device 
(worn 
like 
necklace)
. 
Yes Yes 21 days AF 
identified 
in n=2 
patients.  
Yes.  
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ECG 
screenin
g (multi 
lead) 
Holter 24 
monitors 
Sampaio et 
al, 2018. 
Brazil Not 
reported. 
N=52 
(n=26 
controls 
+ N=26 
stroke 
Clinical trial DMS 300-8 
and DMS 300-
9  
Analysis 
software: 
DMS 
CardioScan II 
software (DM 
Software Inc.  
Stateline, NV, 
USA)  
Transmission 
software: 
Policardiógraf
o IP®, PoIP, 
eMaster, Belo 
Horizonte, 
MG, Brazil  
1 device.  
Single 
lead 
monitor.  
Yes Yes 24-hour Holter.  Equal 
performa
nce noted 
between 
PoIP and 
Holter 
within the 
first 24 
hours.   
AF noted 
in n= 1 
patient 
with 
holter and 
n= 7 
patients 
with PoIP. 
(-) data 
transmissi
on issues 
noted. 
Yes. Used 
Holter 
monitor 
only. . 
Potential 
for PoIP 
technology 
to be used 
with other 
technology. 
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Single 
lead 
monitor 
and 
continuou
s ECG 
recorder.  
Sejr et al, 
2019. 
Denmark 2013-
2017 
N= 1412  
 
prospective 
cohort study  
 
R.Test 
Evolution 4 
(NorDiaTech, 
Paris, France) 
&  
Life Card CF 
digital ECG 
recorder from 
Spacelabs 
Healthcare 
Diagnostic 
Cardiology.  
 
 
2 devices: 
Single 
lead 
monitor 
and 
continuo
us ECG 
recorder 
Yes Yes 2-day 
continuous 
recording  
N=32 in 
ELR 
recordings 
and 
continuou
s 
recording  
? 
Automatic 
external 
loop 
recorder 
not 
considered 
appropriate 
as single 
tool for 
screening 
for AF. (-) 
ECG 
screenin
g (multi 
lead) 
Holter 
monitor.  
Bedside 
ECG.  
Ross et al, 
2018. 
Not 
reported. 
2013-
2014.  
N= 1,153 
 
Study  Not stated.  
Analysis 
software:  
Apoplex 
Medical 
2 devices:  
Holter 
monitor.  
Yes Yes Bedside ECG 
monitoring. 24 
h Holter ECG 
 
Results 
differed 
between 
risk of AF 
in those 
Stroke 
analysis 
software 
found to be 
highly 
112 
 
Technologies, 
Pirmasens, 
Germany) 
Bedside 
ECG. 
& 
analysis 
software 
(stroke 
risk 
analysis, 
SRAclinic[
C], 
Apoplex 
Medical 
Technolo
gies, 
Pirmasen
s, 
Germany
) 
with PAF 
and 
persistent.  
289 
identified 
as having 
a medium 
– high risk 
of AF.  
sensitive at 
detecting 
risk of AF 
but cannot 
be used 
alone to 
diagnose 
AF.   
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
ECG and 
Holter 
monitor 
Sanak et al, 
2015. 
Czech 
Republic  
 
2011-
2014. 
N=105 Study.  24-hour 
Holter 
monitor: 
Philips-Zymed 
DigiTrack 
plus/DigiTrac
k XT (Philips, 
Netherlands)  
&  
 3-weeks 
Holter = MDT 
Vitaphone 
Loop 3100 BT 
(Vitaphone 
GmbH, 
Germany  
ECG type not 
stated.  
3 devices.  
ECG and 
Holter 
monitor.  
Yes. Yes.  
 
24-hour Holter 
monitor and  
3 weeks Holter 
monitor.  
N=9 PAF 
identified.  
3 weeks 
screening 
increased 
screening 
rate.  
ECG 
screenin
g (single 
lead) 
Holter 
monitor 
and ECG.  
Arevalo-
Manso et 
al, 2016. 
Spain.  2011-
2012.  
N=76.  Observational 
study.  
ECG: 
DASH 2500, 
General 
Electric 
2 devices.  
ECG 
monitor 
and 
Yes.  Yes. Continuous ECG 
monitoring 
performed for 2 
days.  
N=20 
individual
s 
Arrhythmia 
software 
noted to 
identify 
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&  
ECG 
screenin
g (multi 
lead) 
Healthcare 
with 
software; GE-
EK Pro 
arrhythmia 
algorithm 
v.11  
 
OR 
Mod. 90369, 
Spacelabs 
Healthcare, 
Issaquah, 
Washington, 
USA  
Cardiac 
monitor:  
DASH 5000, 
General 
Electric 
Healthcare, 
Milwaukee, 
Wisconsin, 
USA  
Holter 
monitor.  
 
Holter monitor; 
24 hours.  
identified 
with AF.  
more 
episodes of 
AF 
compared 
to other 
equipment.  
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Holter & 
12 lead 
ECG.  
Thakkar 
and 
Bagarhatta 
2014. 
India.  Not 
Reported
.  
N= 52.  Study.  24-hour 
Holter 
monitor: 
SCRIBE, 
Mortara in-
struments, 
Inc. 
Milwaukee 
USA 
 
12 lead ECG; 
not reported.  
2 devices; 
Holter & 
12 lead 
ECG.   
Yes.  Yes.  Holter monitor; 
24 hours. 
N=3 
individual
s 
identified 
with AF.  
Screening 
consecutive 
patients led 
to the 
identificatio
n of AF.  
ECG 
screenin
Holter & 
12 lead 
ECG. 
Suissa et al, 
2014. 
France.  2011-
2012.  
N=362.  Prospective 
observational 
study.  
Infinity M300 
telemetry for 
the 
conventional 
2 devices: 
ECG and 
Holter.  
Yes. Yes.  Few hours in 
non-AF 
patients.  
N=22 
individual
s 
Early and 
continuous 
monitoring 
associated 
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g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
stroke unit 
area.  
12 lead ECG: 
not reported.  
identified 
with AF.  
with 
diagnosis of 
AF.  
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor & 
12 lead 
ECG.  
Higgins et 
al, 2013. 
United 
Kingdom 
(Glasgow
).  
2010-
2011.  
N=100.  Randomised 
Controlled Trial.  
Novacor R-
test Evolution 
3 device 
 
2 devices: 
  Novacor 
R-test 
Evolution 
3 device 
 
& ECG.  
Yes. Yes.  24 Holter 
monitor and 7-
day cardiac 
monitoring.  
N= 44% 
PAF 
noted.  
 Yes. 
Continued 
monitoring 
advantageo
us in this 
population.  
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor & 
12 lead 
ECG.  
Yodogawa 
et al, 2013. 
Japan.  2006-
2011. 
N=68.  Prospective trail,  DX-
6521(Fukuda
DenshiCo.Ltd.
,Tokyo,Japan 
ECG type not 
reported.  
 
2 devices.  Yes. Yes.  24-hour Holter 
monitor.  
7 
asymptom
atic 
patients 
identified 
as having 
AF.  
Yes.  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor.  
Gaillard et 
al, 2010. 
Not 
reported.  
Note 
reported.  
N=98.  Study. Not reported 
in abstract. 
Not 
reported 
in 
abstract.  
Yes. Yes.  Post 24 hour.  N=9 
individual
s notes to 
have AF.  
NB. Not 
able to 
open full 
article. 
Note: this 
study 
considered 
patient 
population 
after stroke 
whose 
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Holter 
monitor 
was 
negative. 
++ 
ECG 
screenin
g (multi 
lead) 
Holter 
monitor.  
Riley et al, 
2014. 
USA.  Not 
reported.  
N=1990 Study.  Transtelepho
nic ECG 
monitoring 
(TTM). Type 
not specified.  
1 device; 
not 
reported 
Yes.  Yes.  3-week at 6 and 
12 months 
follow up.  
N=12 with 
stroke had 
AF 
diagnosed
.  
No. Mainly 
focused on 
stroke risk 
after 
ablation.  
ECG 
screenin
g (multi 
lead) 
Holter 
Monitor.  
Grond et al, 
2013. 
Germany 
(multi 
centre) 
2010-
2011.  
N= 1135 
 
Prospective 
cohort study.  
Holter 
Monitor. 
Lifecard CF, 
Spacelabs 
Healthcare, 
Issaquah, WA. 
1 device: 
Holter 
monitor.  
Yes.  Yes.  72 Holter ECG.  N=49 
individual
s 
diagnosed 
with AF 
with up to 
72 hours 
of 
screening.  
Yes. 
Improved 
screening 
of AF in 
asymptoma
tic patients.  
ECG 
screenin
g (multi 
lead) 
Holter 
Monitor 
Wachter et 
al, 2013. 
Germany
.  
 N=281.  Prospective 
observational trial 
 
Not reported.  1 device.  Yes. Yes.  7-day Holter 
monitor.  
N=33 
individual
s had AF 
noted as a 
result of 
screening.   
Yes.  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor.  
Miller et al, 
2013. 
United 
States of 
America.  
2009-
2011.  
N=156.  Retrospective 
analysis 
 
 CardioNet® 
(CardioNet, 
Conshohocke
n, PA, USA 
 
1 device.  Yes. Yes.  1-30 days of 
monitoring 
N=27 
individual
s noted to 
have AF.   
Yes. Mailed 
to patient. 
Self-
adhered. 
Results 
indicated 
21 days of 
screening 
needed.  
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ECG 
screenin
g (multi 
lead) 
Holter 
monitor.  
Alhadramy 
et al, 2010. 
Not 
stated 
(not, 
correspo
nding 
author 
Canada) 
2005-
2006.  
N= 1128 
 
Retrospective.  Not stated.  One 
device; 
Holter.  
Yes.  Yes.  Not stated; 
Mean time 22.6 
hours.  
N= 39 
individual
s noted to 
have AF.  
Yes. Not the 
focus but in 
the 
discussion, 
they argue 
and quote 
someone 
else, that if 
the person 
is screening 
within 72 
hours after 
stroke, this 
improves 
screening 
rates.  
ECG 
screenin
g (multi 
lead) 
ECG.  Deif et al, 
2013. 
Australia.  2011.  N= 2802 
 
Study.  Not stated.  2 devices.  Yes.  Yes.  Single ECG 
recording.  
N= 12 No. Not 
continuous.  
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor & 
12 lead 
ECG. 
Suissa et al, 
2013. 
France.  2007-
2010.  
N= 1166  
 
Study. Infinity 
Central 
Station 
(Dr€ager, 
L€ubeck, 
Germany) 
 
ECG type not 
specified.  
 
2 devices.  Yes. Yes.  24 hour 
monitoring.  
N=96 
diagnosed 
with AF.  
Yes. 
Continuous 
monitoring 
whilst in 
hospital 
noted to be 
beneficial 
at 
diagnosing 
AF.  
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ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor 
and 12 
ECG.  
Gumbinger 
et al, 2012. 
Germany
.  
Not 
reported.  
N= 370 
 
Pilot study.  Infinity Delta; 
Draeger 
Medical 
Systems Inc., 
Luebeck,Ger
man 
 
3 devices; 
Bedside 
monitor, 
ECG and 
Holter 
monitor.  
Yes. Yes.  24 hours. N-44 
individual
s noted to 
have AF.  
Yes. For 
discussion. 
Read 
discussion, 
Holter 
monitor 
noted to 
have no 
additional 
benefit 
compared 
to 
continuous 
monitoring 
ECG with 
intermitten
t analysis by 
trained 
staff.  
ECG 
screenin
g (single 
lead) 
& 
ECG 
screenin
g (multi 
lead) 
Holter 
monitor 
and 
bedside 
ECG 
monitorin
g.  
Sposato et 
al, 2012. 
Argentin
a  
 
2007-
2008.  
N=155.  Retrospective.  Holter: 
Infinity 
telemetry 
system 
(Dra ̈ger 
Medical, 
Telford, PA.  
Hospital 
Bedside 
monitors: 
Infinity Vista 
XL  
ECG; 
Marquette 
Dash 4000 
Pro (GE 
Health- care, 
Chalfont St. 
Giles, UK), 
and Eagle 
4000 (GE 
Health- care) 
2 devices.  Yes. Yes.  Note stated; 
appears 3 days 
admission for 
most patients. 
71% of patients 
diagnosed 
within 24hrs.  
N=21 
patients 
diagnose 
with AF.  
Yes. 
Immediate 
and 
Continuous 
monitoring 
improves 
AF 
screening 
rates.  
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multi-lead 
ECG patient 
monitors  
ECG 
screenin
g (single 
lead) 
&  
ECG 
screenin
g (multi 
lead) 
Holter 
monitor; 
ECG and 
continuou
s ECG 
bedside 
monitorin
g.  
Lazzaro et 
al, 2012. 
United 
States of 
America.  
2007-
2008.  
N=133.  Study.   Not stated.  3 devices.  Yes. Yes.  22-24 hours of 
monitoring.  
N=5 
individual
s 
identified 
to have 
AF.  
Yes. 
Screening 
rate of AF 
was noted 
to be higher 
in Holter 
monitor 
than 
Continuous 
cardiac 
telemetry 
(during 
hospitalisat
ion)  
Note: 
discussion 
states 
although 
the length 
of 
assessment 
is 
important, 
the type of 
device 
used, and 
the 
expertise of 
the person 
analysing is 
also 
important.  
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ECG 
screenin
g (multi 
lead) 
Continuou
s 12 lead 
ECG. 
Fernandez 
et al, 2014. 
France. 2012. N=187. Study  12 lead ECG: 
CSM Philips 
IntelliVue 
MP50 system, 
24-hour ECG 
monitoring  
1 device: 
ECG.  
Yes. Yes. 24 hours. N=19 
individual
s 
identified 
with AF.  
Continuous 
screening 
identified 
AF.   
ECG 
screenin
g (multi 
lead) 
ECG 
(bedside 
monitor) 
Scheitz et 
al, 2015. 
Not 
reported.  
2011-
2013. 
N= 1228  
 
Study.  Bedside 
patient 
monitor 
Philips, 
IntelliVue 
MP50 
 
1 device. 
ECG. 
Yes. Yes. 2-4 days 
monitoring.  
Unknown 
AF 
identified 
in n=114 
(-) Bedside 
monitoring. 
Cost 
implication
s. Impact on 
daily 
activities.  
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Appendix 4: Criteria for Device 
 
• The device can be used outside of a hospital setting. 
• It is easy to use. 
• Device itself, and the data gathered on it, should not leave Scotland, ideally held on NHS premises and 
the company accesses the data from there. 
• It is CE marked. 
• Cost is ideally less than £400 for 14-day monitoring period. 
• Data transferred to a cloud space. 
• Ideally multi-use. 
 
 
Criteria category   Definition/ criteria of Assessment  
CE marking?  If a device is marked with the initials CE (Conformité Européene), this ensures the 
device confirms to European standards of safety. Such a requirement is essential 
for use within the NHS and for use within the public population (GOV, 2018).  
Recording time. Recording time should be documented. For purposes of this study 72 hours of 
continuous recording time is required.  
Available for home use? Available to be purchased and used within home environment (not requiring 
hospital stay) 
Evidence of ease of use? Evidence of feedback regarding the ease of using the device (application, charging, 
reapplying etc).  
Evidence of patient 
comfort? 
Evidence of feedback regarding the comfort of the device (specifically no evidence 
of skin irritation when wearing the device).  Evidence of being user friendly.  
Specificity/ sensitivity Evidence of the ability of the device to identify AF.  
Single/multi-use? Evidence on whether the device is single or multipurpose use.  
Single use: infection control implications reduced.  
Multi use: reusable devices can be used on more than one patient; more cost 
effective.       Easy to clean? 
Cost? Price is documented.  
Control of data? Documented evidence of:  
Who owns the data? 
What data is collected? 
Where is the data sent and stored? 
When is the data deleted? 
How is the data transferred and reported? 
Battery  Chargeable?        Battery length?  
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Appendix 5: Screening and Recruitment Procedure 
   
Screening:
Patients suitability screened by clinical 
team: i.e. treating consultant/stroke 
specialist nurses/research team (such as 
research nurses). 
Information given:
Patients given PIS and copy of consent 
form by ward staff/consultant/clinical 
specialists/ research nurses. Contact 
details of UoS included in PIS. 
Referral:
Patient given contact details of UoS and 
requested to contact research team or 
patients name and contact details will be 
passed onto UoS research team by clinical 
team via email or over the telephone(if 
patient provides consent to be contacted 
to further discuss the study). 
UoS Initial Contact:  
UoS contacted or UoS contacts participant 
to discuss study over the phone/ arrange 
suitable time for meeting. 
Consent: 
Consent to be taken by Research 
Assistant/ Research Associate (UoS/GSA) 
prior to interview. This can be completed 
over the phone. 
Interview: 
Interview conducted with participant 
(over the phone/in person) in persons 
home/ hospital outpatient setting/UoS 
grounds/ at a time and place which is 
most convenient to patient. UoS team 
liase with clinical team to arrange the 
interview to be on the same day as other 
appointments if possible to reduce patient 
burden. Completed by UoS team. 
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Appendix 6: Flow chart: Screening and Recruitment Procedure  
Screening
n=67
Information given
n=67
Patients who took part by wearing device
n= 64
Individuals who contacted UoS 
n= 11
Reasons for not wishing to take part: 
- not interested (n=2)
- HCPs felt participation would cause 
distress (n=1)
UoS Consent 
n= 8 (patients) & n=1 (relative)
Interview 
n= 8 (patients) & n=1 (relative)
Reasons for not wishing to take part: 
- seeking information about their 
clinical results: not interested (n=1).
- not interested (n=1).
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Appendix 7: Schedule of Procedures 
As outlined throughout the protocol to explore the current pathway, patients may take part in Part One or Part two. NB: There is a different 
inclusion and exclusion criteria applied to each part of this study.  
Please note, participant may take part in data collection on one or more occasions. Research procedures which are highlighted in brackets may 
be performed several times during the project. The number of times any of the methods is repeated, is dependent on consent given and the 
participants’ availability. ** = Activity performed by HCP
Procedures PART ONE: Current Practice (led by GSA) (Also referred to as Work 
Package 1) Patients with previous diagnosis of AF  
PART TWO: New Device(s)/Future (led by UoS) (Also referred to as Work Packages 2-4) Patients 
with no previous diagnosis of AF 
Screening Baseline Follow up 1 (GSA) Screening Baseline (Part 2) Follow up 1 
(UoS) 
Follow up 2 Follow up 3 
Initial approach screening  **X   **X     
Preliminary consent to 
contact 
**   **     
Informed consent  X   X    
Demographic/ medical 
history 
 X   X    
Quantitative Data 
Collection: Observation of 
care pathway 
 X X  X (x) (x) (x) 
Quantitative Data 
Collection: Survey 
  X   (x) (x) (x) 
Qualitative Data Collection: 
Focus Group 
  X   (x) (x) (x) 
Qualitative Data Collection: 
Interview (phone/face to 
face) 
  X   (x) (x) (x) 
Qualitative Data Collection: 
Interactive Workshop  
  X   (x) (x) (x) 
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Schedule of Procedures: Other Participants  
  
Procedures PART ONE: Current Practice (led by GSA) (Also referred to as 
Work Package 1) Observation of patients with previous 
diagnosis of AF  
PART TWO: New Device(s)/Future (led by UoS) (Also referred to as Work Packages 2-4) Observation 
of patients with no previous diagnosis of AF 
Screening Baseline Follow up 1 (GSA) Screening Baseline (Part 
2) 
Follow up 1 
(UoS) 
Follow up 2 Follow up 3 
Initial approach screening  **X   **X     
Preliminary consent to 
contact 
**   **     
Informed consent  X   X    
Demographic/ medical 
history 
 X   X    
Quantitative Data 
Collection: Observation of 
care pathway 
 X X  X (x) (x) (x) 
Quantitative Data 
Collection: Survey 
  X   (x) (x) (x) 
Qualitative Data 
Collection: Focus Group 
  X   (x) (x) (x) 
Qualitative Data 
Collection: Interview 
(phone/face to face) 
  X   (x) (x) (x) 
Qualitative Data 
Collection: Interactive 
Workshop  
  X   (x) (x) (x) 
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Schedule of Procedures: Healthcare Professionals (HCP) 
 
Procedures PART ONE: Current Practice (led by GSA) (Also referred to as 
Work Package 1) Observation of patients with previous 
diagnosis of AF  
PART TWO: New Device(s)/Future (led by UoS) (Also referred to as Work Packages 2-4) Observation 
of patients with no previous diagnosis of AF 
Screening Baseline Follow up 1 (GSA) Screening Baseline (Part 2) Follow up 1 (UoS) Follow up 2 Follow up 3 
Initial approach 
screening  
X   X     
Informed consent  X   X    
Demographic/ 
medical history 
 X   X    
Quantitative Data 
Collection: 
Observation of 
care pathway 
 X X  X (x) (x) (x) 
Quantitative Data 
Collection: Survey 
  X   (x) (x) (x) 
Qualitative Data 
Collection: Focus 
Group 
  X   (x) (x) (x) 
Qualitative Data 
Collection: 
Interview 
(phone/face to 
face) 
  X   (x) (x) (x) 
Qualitative Data 
Collection: 
Interactive 
Workshop  
  X   (x) (x) (x) 
126 
 
Appendix 8: Amendment History 
Study Name:  ___________________________________ 
 
Amendment 
Number 
Protocol 
Version 
Date of 
Amendment 
(submission 
&approval) 
Amendment 
Type (Major 
/ Minor)  
Author(s) Amendment 
Summary 
Justification 
for 
Amendment 
       
       
       
       
       
       
       
 
NB: Any protocol amendments will be submitted to the Sponsor for approval prior to 
submission to the REC.  
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Appendix 9: Telephone Interview Process 
 
Introductions (name and role within UoS) & confirmation of suitability of time (e.g. Is now a 
good time to speak, or would you like me to call you back at a better time?)  
Thank you for agreeing to take part in this interview.  
Did you get the information leaflet about the research study from the nurse from NHS 
Lanarkshire? The hospital is using a different heart monitor device and the University of 
Strathclyde is looking at how this new service has gone. We would like to ask you some 
questions about how you found the heart monitor device. We would like to ask about 
experiences of wearing the heart monitor device. Have you been able to read the information 
sheet the nurse gave you?  (if yes proceed) (If not, provide opportunity to ring at a different 
day/time or if helpful to patient, offer to read the PIS over the telephone with the patient - 
And then ring back for an interview a different day). Do you have any questions? (Answer 
questions /if no further questions proceed).  
This conversation will be audio recorded to record our conversation. If you are happy, I am 
going to turn on the voice recorder.  
(if yes, turn on voice recorder).  
So, before we begin, I will read some statements. I will ask you to say yes or no for each 
statement.   
Please tell me if you do not understand any statements.  
Please tell me if you would like me to repeat anything.  
We can have a break at any time.  We can stop at any time.  
1. I have read and understood the information sheet  
2. I have had time to think about the information and ask questions.  
3. I am happy with the answers to these questions 
4. I am happy to take part in 1 interview about my experiences.  
5. I understand that I can stop at any time. I do not have to give a reason.  
6. I understand the interview to be audio-taped and typed up. 
7. I understand that research and hospital staff will be told about the study, but my name 
will never be used.  
8. I understand that my GP will be told I am in the study.  
9. I understand that quotes from the interview might be used in academic journals, reports, 
and conferences. I understand that my name will never be used.  
10. I understand that hospital staff involved in this study might look at my medical notes.  I 
am happy with this.  
11. I am happy to take part in this study.  
 
Can you confirm your name?  
(Turn off recorder) 
 
Note: Start new file for audio recording for the interview.  
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Appendix 10: Topic Guide  
 
Process Evaluation for Technology Enabled Atrial Fibrillation Detection in Secondary Care 
in Scotland: Topic Guide: Patients 
These are the topic guides we will draw on for our qualitative research on patients’ 
experiences of technology enabled atrial fibrillation screening in secondary care in Scotland. 
These questions have been split into two phases to reflect the different work packages (see 
below). These topic guides will influence all of our activities which include interviews (face-
to-face and telephone), focus groups, workshops and surveys. 
Work Package 1 = Current experiences and expectations 
 
1.1 Can you tell me about your stroke? 
Potential prompts (if not mentioned throughout the discussion): 
a) How was it diagnosed?  
b) Can you tell me about your first meeting with a clinician [this could be GP visit 
/specialist consultation for AF/stroke]? 
c) Did you have any treatments for this? If so, where was this? 
d) Did your stroke leave your with any limitations, please specify.  
 
1.2 Did you have investigations for any heart arrhythmias? 
If yes, can you tell us about your experience of this? 
 
1.3 What are your experiences of AF Services/appointments? 
Potential prompts (if not mentioned throughout the discussion): 
a. How/was your heart rate or rhythm monitored by GP or clinicians before your 
diagnosis? 
b. Can you describe this experience? 
c. Do you have any comments about the care? 
 
1.4 What (if any) are your thoughts or experiences of the AF screening device/monitor used 
in your care?  
 
1.5 Would you like to tell us anything else about your experience that we may have missed? 
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Work Package 2 = Experiences with new tech enabled AF service in Lanarkshire 
2.1 Tell us about your experience of using the [AF device] so far?  
Potential prompts (if not mentioned throughout the discussion): 
a) Can you explain, how heard about this device? Who invited, you to take part and how did they do 
this?  
b) What has the device been like so far? 
 
2.2 Can you tell me about your stroke? 
Potential prompts (if not mentioned throughout the discussion): 
a) How was it diagnosed?  
b) Can you tell me about your first meeting with a clinician [this could be GP visit /specialist 
consultation for AF/stroke]? 
c) Did you have any treatments for this? If so, where was this? 
d) Did your stroke leave your with any limitations, please specify.  
 
2.3 Have you ever had similar screening for AF or other heart arrhythmias? 
Potential prompts (if not mentioned throughout the discussion): 
a) Have you used any other products to measure your rate or rhythm (to identify AF or another 
heart arrhythmia)?  
b) If so, can you tell me about this? 
 
2.4 The next questions are asking about your opinion of the introduction of this device to the service.    
Potential prompts (if not mentioned throughout the discussion): 
a) What do you think the purpose of the device is? 
b) How did the use of this device impact your care? 
c) Can you tell me your thoughts about the device? Why? 
d) What did you think of the way the device looked? 
e) What was the device like to wear?  (Further prompt: if needed) Was it comfortable? 
f) Did you have to alter your activities/life to use this device?) 
g) If it was needed, would you be happy to wear this device again, if so, why?  
 
2.5 What did healthcare professionals say to you about the [device or service]? 
Potential prompts (if not mentioned throughout the discussion): 
a) Was it all understandable? 
 
2.6 Do you think this device changed your treatment? 
Potential prompts (if not mentioned throughout the discussion): 
a) How? 
 
2.7 Do you think there are any benefits or disadvantages of using this device?  
Potential prompts (if not mentioned throughout the discussion): 
a) How would you feel if you were given the device again? 
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Continued…  
 
2.8 What do you think about using other devices, or technology in your future care to screen or 
diagnose AF? 
Potential prompts (if not mentioned throughout the discussion): 
a) Can you explain these thoughts? 
Further potential prompts (if needed) (if not mentioned throughout the discussion): 
b) What do you think are key things that the technology should be or do to be acceptable to screen 
patients for AF? (Acceptability/easy to use) 
c) Do you have any thoughts about the importance of the usability of the screening device? (Further 
prompt: if needed) is being able to use the device yourself important? 
d) Have you any thoughts about what the device is like to wear?  (Further prompt: if needed) is 
comfort important? (comfort)  
e) Do you have any thoughts about trusting the device? (Further prompt if needed, to screen for 
AF/or about the storage of data?) (trust) 
 
2.9 Based on your experiences, what could help make the experience better in the future? 
 
3.0 Would you like to tell us anything else about your experience that we may have missed? 
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Appendix 11: Arrangement for Lone working (UoS) 
 
This guidance document was developed based upon guidance provided from the University 
of Strathclyde (Travel and Work Off University Campus: Staff and Students, June 2013). 
It is preferred that researchers will attempt to conduct data collection activities in person (at 
local hospitals/NHS premises) or over the telephone. If the participant is unable to attend a 
local healthcare facility in person and does not wish to have a telephone phone call, the 
interviewer will at this stage offer to conduct an interview at the interviewees’ home.  
If this occurs the researcher(s) will follow the below pathway.  
Prior to interview the relevant line manager/ colleague will be informed of:  
• location of interview (address),  
• time of commencement of interview, 
• anticipated time of finishing, 
• contact details of interviewer, 
• contact details of interviewee.  
The Interviewer will contact line manager/colleague before the interview and will contact the 
same individual following the interview. If the interview time is anticipated to be later than 
originally planned, the interviewer is expected to contact the colleague / line manager to 
inform them of this change. If the interviewer does not contact the designated person within 
this planned time frame, the colleague / line manager should first attempt to contact the 
interviewer. If they are not successful at this, the interviewee should be contacted to speak 
to the interviewer. If no contact is available, this should be escalated and advice from senior 
colleagues should be sought. Emergency contacts (University security/police) may be 
required in the event no contact is able to be achieved.  
 
Prior to a conducting a home interview, researchers should complete the relevant risk 
assessment in line with the University of Strathclyde Lone working policy. The individual 
should also complete the relevant insurance document to ensure the University is informed 
of out of office working.  
Any concerns or events should be documented, and the Principle investigator and Sponsor 
informed.  
 
